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Foreword
It gives me particular pleasure to present with this publication the results of
the risk assessment undertaken by the European Monitoring Centre for Drugs
and Drug Addiction (EMCDDA) on the substance ketamine. The risk assessment
was carried out under the terms of a joint action adopted on 16 June 1997
by the Council of the European Union (1) and is the third such exercise
undertaken to date by the EMCDDA (2).
Ketamine is a substance with a large and well-established therapeutic use,
particularly in veterinary medicine, but since the mid-1990s it has surfaced
as a recreational drug. This presented a new challenge for the risk-assessment
committee, that of how to assure a drug’s continued availability for medical
and veterinary use while taking appropriate measures against its diversion to
the illegal drugs market for illicit use and the associated health risks.
Information on the patterns of use and implications for illegal drugs trafficking
networks were collected through the EMCDDA’s early warning system via
the European network of national focal points and Europol’s national units.
On the basis of the findings, the Horizontal Working Party on Drugs of the
EU Council requested a risk-assessment procedure to be carried out which
reviewed the pharmacotoxicological data on ketamine and assessed the
public health risks and the available sociological and criminological evidence.
The resulting ‘Report on the risk assessment of ketamine’ was presented to
the Council in March 2001. On the basis of the report, the Council requested
the EMCDDA and Europol to continue monitoring ketamine — its manufacture,
(1) Joint action concerning the ‘information exchange, risk assessment and the control of new synthetic
drugs’ (OJ L 167, 25.6.1997). A joint action is a decision adopted unanimously by the EU
Member States within the framework of the third pillar of the Treaty on European Union
(cooperation in the field of justice and home affairs). Synthetic drugs are psychoactive substances
produced in laboratories and not derived from natural products. They include MDMA (ecstasy),
other amphetamines and LSD.
(2) The three previous risk-assessment exercises concerned the substances N-methyl-1-
(1,3-benzodioxol-5-yl)-2-butanamine (MBDB), 4-methylthioamphetamine (4-MTA) and gamma-
hydroxybutyric acid (GHB).
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trafficking, patterns of use and health consequences and particularly trends
in recreational use — until the end of 2001. The Council will then consider
whether control at EU level is appropriate.
I would like to thank all those who participated in the risk-assessment
process for the high-quality work carried out. This makes a valuable scientific
contribution, validated at European level, to the knowledge base on medicines
diverted for illicit use.
Georges Estievenart
Executive Director, EMCDDA
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Introduction
A risk assessment of any chemical is a unique scientific event in which a
range of evidence is evaluated and discussed in depth. Risk assessments of
new synthetic drugs under the aegis of the joint action of July 1997 are even
more unique because not only the pharmacotoxicological effects on health
must be considered but also the social effects and the possible consequences
of prohibition. The risk assessments performed in September 2000 on ketamine
and GHB (gamma-hydroxybutyric acid) were respectively the third and
fourth such risk assessments performed by the extended Scientific
Committee at the European Monitoring Centre for Drugs and Drug Addiction
(EMCDDA). The unique feature of these substances is that they are both
licensed medicines of value in human or veterinary medicine. The task faced
by the risk assessment committee therefore involved not just an assessment
of the scientific evidence but also an assessment of how best to safeguard
public health while simultaneously ensuring that valuable medicines could
still be available to practitioners and their human (and animal) patients.
These assessments involved detailed and robust discussions among the
multidisciplinary committee, which was drawn from each of the Member
States. The ability of scientists from a range of laboratory and non-laboratory
sciences to debate the issues surrounding new synthetic drugs is a key
strength of the joint action process and my colleagues on the Scientific
Committee are to be commended for their detailed and learned contributions
to our overall understanding of these two substances. Their individual contri-
butions, allied to those of the two experts, Dr Leon van Aerts (Ketamine) and
Mr Simon Elliott (GHB), plus the invaluable inputs from the staff of the
EMCDDA, provided the basis for the final recommendations made to
Council about the two drugs. These recommendations do not only relate to
the question of control of ketamine and GHB but also highlight the need for
the Member States to consider other elements such as the need for research
on the neurotoxicity of ketamine and on the role of GHB (and other drugs)
in cases of drug-assisted sexual assault. Given that these subsidiary recom-
mendations come from a committee composed of the leading experts on
new synthetic drugs in the EU, their importance should not be underesti-
mated by the Commission, the Council or the Member States.
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As ever with these risk assessments, an enormous debt of gratitude is due to
my colleagues on the Steering Committee for Risk Assessment who worked
incredibly hard before, during and after the meetings to finalise the reports.
The work of Salme Ahlström (Finland), Aldo Perissino (Belgium), Wolfgang
Werdenich (Austria), Jean-Pol Tassin (France) and Christina Poethko-Müller
(Germany) was more than matched by the efforts of the staff of the EMCDDA,
including Alain Wallon, Lena Westberg and Deborah Olszewski.
My admiration for all of them has grown with each risk assessment because
of their acumen, commitment and enthusiasm for a unique European activity.
Dr Desmond Corrigan
Chairperson, Scientific Committee of the EMCDDA
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9Report on the risk assessment of ketamine 
in the framework of the joint action on new
synthetic drugs
On 17 April 2000, the Portuguese Presidency of the European Council
formally notified ketamine (2-(2-chlorophenyl)-2-(methylamino)-cyclohexa-
none) to the EMCDDA for risk assessment under Article 4 of the joint action
on new synthetic drugs of 16 June 1997.
A meeting of the Scientific Committee of the EMCDDA, extended with
experts nominated by the Member States and representatives of the
European Commission, Europol and the EMEA (European Agency for the
Evaluation of Medicinal Products), to assess the health and social risks as
well as the possible consequences of prohibition of ketamine, was held on
25 and 26 September 2000.
The meeting considered the following documents:
 ‘The pharmacotoxicological report on ketamine’, report to the EMCDDA;
 ‘Public health risks: epidemiological evidence’, EMCDDA;
 ‘Sociological/criminological evidence’, EMCDDA;
 Europol’s contribution to the risk assessment of ketamine;
 EMEA’s contribution to the risk assessment of ketamine.
These documents, in conjunction with further information and comments
from the expert participants, formed the basis of the risk assessment reported
below.
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1. Chemical description
The chemical name of ketamine is 2-(2-chlorophenyl)-2-(methylamino)-
cyclohexanone, an arylcycloalkylamine. It is structurally related to phency-
clidine (PCP: ‘angel dust’) and cyclohexamine. It occurs in racemic form and
also as the S-enantiomer.
Registered names (for human use) are: Ketalar, Ketamine Panpharma,
Ketolar, Ketanest-S.
Registered names (for veterinary use) are: Ketalar, Ketaminol Vet., Clorketam,
Imalgene, Anesketin, Ketamine Ceva, Vetalar Vet., Narketan, Ketaset.
Ketamine is known in Member States by the street names: K, special K, 
kit kat, tac et tic, cat valium, vitamin K, ket, super K and others.
2. Pharmaceutical description
Ketamine was first synthesised in 1962 and patented in Belgium in 1963. 
As an anaesthetic and analgesic, ketamine has a recognised unique therapeutic
value in veterinary practice and, to a lesser extent, in human medicine. 
For therapeutic purposes, ketamine usually is administered intravenously or
intramuscularly.
In recreational use, typical doses are: 75–125 mg intramuscularly or subcutane-
ously; 60–250 mg intranasally; 50–100 mg intravenously; and 200–300 mg
orally.
Ketamine is manufactured by the chemical industry for use in the manufacture
of pharmaceutical products which use as precursors cyclopentyl bromide, 
o-chlorobenzonitrile and methylamine. Due to the complicated multi-step
synthesis, and the difficulty of purchasing the necessary precursors and
numerous solvents and reagents, ketamine sold illicitly for recreational use
appears to be mostly obtained by diversion of legitimate supplies of either
the bulk drug or of pharmaceutical preparations containing it.
Pharmaceutical products may be injected or may be modified by evaporation,
after which the resultant powder may be snorted in pure form or mixed with
other drugs and/or inactive components. In powder form, combination with
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cocaine has been observed. In the form of tablets, the concentration of
ketamine and other substances is mostly unknown by users. These tablets are
sold as ‘ecstasy’ in some Member States. Other substances reported to be
present in tablets containing ketamine are pseudoephedrine, ephedrine,
caffeine, amphetamine, methamphetamine and MDMA. As the effects of
ketamine are dose-dependent, the fact that the amount of ketamine concen-
trated in the powder (and a fortiori in fake ‘ecstasy’ tablets) is unknown poses
a risk in recreational use.
Preparations containing ketamine hydrochloride are used as an anaesthetic
and analgesic agent in human and veterinary medicine, with important clinical
applications in paediatric and ambulatory anaesthesia, treatment of burn-
wound patients and for short anaesthetic procedures. However, the use of
ketamine for humans in the EU is restricted to special indications, due to the
occurrence of emergence reactions. Outside the EU, its ease of use gives
ketamine a major advantage under difficult circumstances (developing
countries and remote areas). Its use in veterinary anaesthesia, especially for
small animals, is widespread and considered by several Member States and
by the Federation of Veterinarians of Europe as indispensable in veterinary
medicine.
3. Health risks
3.1. Individual health risks
(a) Acute effects: Ketamine is a dissociative anaesthetic. The term ‘dissociative’
has two meanings. Firstly, it refers to an effect on the brain, inducing a lack
of responsive awareness, not only to pain but also to the general environ-
ment. Secondly, it refers to a feeling of dissociation of the mind from the
body (‘out-of-body experience’). Ketamine would be expected to block or
interfere with sensory input to centres of the central nervous system (CNS);
in a way, the drug selectively interrupts association pathways of the brain
before producing somaesthetic (sensation of having a body) sensory blockade.
Ketamine differs from most anaesthetic agents in that it appears to stimulate
the cardiovascular system, producing changes in heart rate, cardiac output
and blood pressure. In recreational ketamine users presenting themselves to
an emergency department, tachycardia was the most common finding. As a
mild respiratory depressant, ketamine is unlikely to produce respiratory
depression at recreational doses, even if this cannot be wholly excluded.
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Cardiovascular effects usually do not pose a problem in patients without
cardiovascular problems, but ketamine is contraindicated in patients with
significant ischaemic heart disease and is to be avoided in those with a history
of high blood pressure or cerebrovascular disorders.
The findings of neurotoxicity in the rat may indicate some cause for concern
in recreational users of ketamine. These users may not take ketamine in com-
bination with protective agents like benzodiazepines, as is usually the case
in the clinical setting. Moreover, compounds increasing the neurotoxic
potency of ketamine (like alcohol) might be co-administered. Recreational
use also implies repeated exposure, whereas clinical use is mostly incidental.
Long-term adverse effects in chronic users of ketamine have been reported,
though rarely, and these include persistent impairment of attention and recall
and a subtle visual anomaly. The Report on the risk assessment of 4-MTA
noted that ketamine increased the neurotoxicity of 4-MTA in mice.
Neurotoxicity of repeated exposure to ketamine in primates including
humans has not been studied.
(b) Clinical effects: Ketamine is considered to be an anaesthetic with a good
safety profile, based on extensive clinical experience. The major drawback,
which limits clinical use, is the occurrence of emergence reactions in
patients awakening from ketamine anaesthesia. These reactions include
hallucinations, vivid dreams, floating sensations and delirium. However,
preclinical data on the effects of repeated ketamine administration may be
of greater importance for recreational use, which, unlike clinical practice,
may present cases of long-term use.
A total of 12 deaths in which ketamine was identified were noted between
1987 and 2000, including seven from the United States. Only three reported
fatal cases involving ketamine alone were identified. Two reports concern
mixed drugs fatalities. In one case, ketamine had only a minor role. For the
remaining six cases, insufficient details were available to be evaluated properly.
In the three cases involving only ketamine, the routes of administration were
intramuscular or intravenous and the cause of death was mainly overdose
(multiple intramuscular doses or accidental intravenous overdose), in line
with preclinical findings. In the other cases involving ketamine mixed with
other drugs, the observed lower ketamine concentrations indicate that drug
interaction may have contributed to these deaths. Substances with CNS/
respiratory depressant effects, like ethanol, opioids, barbiturates and benzo-
diazepines, or drugs with cardiostimulant effects, like cocaine or ampheta-
mines, may increase ketamine acute toxicity.
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Regarding non-fatal intoxications, potential dangerous interactions may also
arise when different drugs are combined. Ketamine has sympathomimetic
properties. Inhibition of central catecholamine re-uptake and increased levels
of circulating catecholamines are believed to cause the cardiovascular stim-
ulant effects. Serious side-effects such as hypertension and pulmonary oedema
have been reported, but such adverse effects appear to be rare and may be
related to the combination of ketamine with other drugs, such as ampheta-
mine and its analogues, ephedrine and cocaine.
(c) Dependence: Tolerance, dependence and withdrawal signs have been
observed in a number of animal studies. Tolerance to the desired effects of
ketamine develops quickly and may result in an escalation of the dose, the
toxicological implications of which are unknown. A risk associated with the
recreational use of ketamine is the potential of the drug to cause psychological
dependence in some individuals, based on case reports and information
from users. The prevalence of long-term use is unknown. There is no evidence
that ketamine causes an abstinence syndrome in humans.
(d) Psychological effects: The recreational user of ketamine may experience
an altered, ‘psychedelic’ state of mind (‘the K-hole’) that allows the user 
to travel beyond the boundaries of ordinary existence. The intensity of 
‘psychedelic effects’ is dose-related. Ketamine in subanaesthetic doses pro-
duces a clinical syndrome which both neurophysiologically and behav-
iourally resembles that of a schizophrenic psychosis. Ketamine acutely
affects cognitive performance and profoundly affects perception of the body,
time, surroundings and reality.
The main effects of ketamine are neurobehavioural: anxiety, agitation,
changes of perception (e.g. loss of sense of danger, visual disturbances),
impairment of motor function and the analgesic effects. In such a condition, the
user may be at risk of injury to themselves (burns, falls) or to others (accidents).
14
3.2. Public health risks
(a) Availability and quality: Ketamine preparations have marketing authori-
sations in most countries of the EU, except in Greece where the marketing
authorisation was recalled in 1998 (3). Seizure data suggest mostly low levels
of availability of ketamine for illicit use within different Member States, with
a decrease occurring in the United Kingdom and an increase in two other
Member States. A large proportion of ketamine seizures are in tablet form
and the tablets carry the same logo as is often used for ecstasy tablets. It may
also be found in powder form and sold as a stimulant, such as amphetamine
or cocaine. Forensic laboratories have found ketamine in variable doses
mixed with manitol, caffeine, ephedrine and pseudoephedrine, MDMA,
methamphetamines and amphetamines. In Belgium, 89 kg of pure ketamine
powder was seized in September 1999 and a further 3 kg in January 2000.
Four Member States (Belgium, Ireland, the Netherlands and the United
Kingdom) seized significant amounts of ketamine. However, seizures of
ketamine are small when compared to seizures of ‘regular’ types of synthetic
drugs, such as amphetamine, MDMA and MDA.
(b) Knowledge and perception of ketamine among users: There appears to be
low awareness of and experimentation with ketamine in Europe compared
with drugs such as cannabis, MDMA, amphetamine and cocaine. Lack of
information about the dose content of the ketamine on the market may be
an important factor. Anecdotal reports from France and the United Kingdom
indicate growing awareness among consumers about how to manage doses
to achieve the desired effects and to avoid negative ones. A survey in a
dance setting in Austria found that the respondents who regularly use
MDMA and amphetamines considered the psychological risks attached to
ketamine to be very high.
At low doses, ketamine is sometimes reported to have a stimulant effect. This
could be the result of the stimulant effect of other drugs or active cutting
agents (like caffeine), because ketamine is often snorted with amphetamines
and/or cocaine or taken with other drugs in the illicit drug scene. There is
some indication that ketamine has an upmarket image as an esoteric drug for
experienced drug users.
(3) Classification for the supply of medicinal products for human use is regulated by Directive 92/26/EEC
of 31 March 1992. Article 12 of Directive 75/319/EEC of 20 May 1975 regulates, through the
Committee for Proprietary Medicinal Products (CPMP), the suspensions, withdrawal or variations
to the terms of the marketing authorisation, in particular to take account of the information collected
in accordance with pharmacovigilance. 
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(c) Prevalence and patterns of use: Surveys of selected groups of drug users
in dance settings have shown that a significant number of people experiment
with ketamine but that the level varies between sub-populations and geo-
graphical areas. A London club survey in 1997 found that up to 40 % of the
200 respondents had experimented with ketamine and were to use it that
same evening. A large French survey conducted the same year found that
15 % of the 900 respondents in techno party settings had experimented with
ketamine. Recently, a large school survey conducted in the north-east of
England found that 1 % of 13/14-year-old children and 2 % of 15/16-year-
olds had tried ketamine compared to 2 and 5 % respectively who had tried
cocaine.
The most popular routes of administration are to snort ketamine as a powder
and to inject liquid preparations. There have also been reports of it being
swallowed, smoked or inserted rectally.
(d) Characteristics and behaviours of users: Although there is evidence of use
by younger people, targeted surveys and anecdotal reports indicate that
prevalence may be higher in older, highly educated, experienced MDMA
users, particularly in the free party/new-age traveller scene, in the gay club
scene and among small groups of self-exploratory individuals. Among
‘closed’ groups in Europe, initiation into ketamine use is often ritualised.
The most vulnerable group is those who take ketamine under the illusion
that they are taking MDMA or some other stimulant drug. The volume of
seizures of ketamine in tablet form with ecstasy-type logos reflects the scope
for this scenario and the need for better information about drug contents and
harm reduction. Ketamine does not react with commonly used field tests
(e.g. Marquis reagent), although other drugs present in the tablet may
produce a positive reaction.
(e) Indicators of health consequences: Four deaths in the EU in which ketamine
was found by laboratory analysis have been reported to the EMCDDA since
1996, of which two occurred in 1996, in Ireland. In neither of the Irish 
cases was ketamine considered to be the main cause of death. The death of
a 19-year-old male has been reported in France where ketamine, LSD and
ecstasy were implicated. The fourth death, also reported from France, was a
polydrug user.
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There has been a notable lack of reporting about hospital emergencies in
Europe. A recent report in France presents some data on 17 cases of intoxi-
cation associated with ketamine.
An important factor of health risk is the lack of reliable indications of dose
accompanying sales of ketamine at street level. In the absence of advice,
first-time users of ketamine tend to follow similar consumption patterns as
those previously adopted for other drugs. This uninformed use of ketamine
increases the risk of both physical and psychological problems. The exis-
tence of tolerance may increase a tendency to move from snorting to injecting
ketamine, with the risks associated with injection.
(f) Context of use: The phenomenon of ketamine entering the recreational
drug market in the guise of ecstasy or other stimulant drugs means that someone
expecting to take MDMA, cocaine or amphetamine may find themselves
inadvertently taking ketamine, without warning, knowledge or support.
Compared to the effects of stimulants, the rapid physical incapacity induced
by ketamine consumption has serious implications for driving.
4. Social risks: sociological and criminological aspects
4.1. Sociological aspects
(a) Social consequences: The main social consequences for the user stem
firstly from its anaesthetic properties and loss of physical control if too high
a dose is taken, and secondly from reported psychological effects of either
regular or heavy use, which include dependency. In addition to loss of physical
control, it may cause tension due to the introspective quality of effects, other
psychological symptoms and compulsive use by a small minority.
(b) Consequences for the social behaviour of the user: The main conse-
quences for social behaviour stem directly from ketamine’s specific effects
and a tendency towards compulsive use by some users.
(c) Other social consequences: In dance settings, ketamine often appears in
the form of well-made tablets which are visually similar to MDMA and are
usually mixed with a stimulant such as caffeine or amphetamine. It is also
found as liquid, powder and capsules. Ketamine has also been used as a cutting
agent for drugs such as cocaine, amphetamine and heroin and may be taken
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by problem opiate users. The chosen route of administration for a small
minority is by injection, which raises a value conflict in a drug-using culture
which is strongly against injecting.
A range of social factors increase the probability of use, such as the existence
of a large market of long-term ecstasy users seeking new drug experiences,
a rather intellectual trend-setting image and low price. However, other factors
mitigate against widespread diffusion, such as the anaesthetic effects,
marked discomfort with intranasal use, the short action, acute psychological
reactions when taken without due knowledge about dose or effects, psycho-
logical dependence and negative effects on social relationships.
In view of its potential anaesthetic and numbing effects, psychological
disturbances and compulsive use, there are implications for drug services,
research institutes, hospital emergency departments and the press.
4.2. Criminological aspects
The seizure of considerable amounts of ketamine in Belgium, Ireland, the
Netherlands and the United Kingdom could suggest the involvement of
organised crime. In the United Kingdom, it is believed that ketamine raw
material is imported in bulk from legitimate suppliers in Europe. A number
of sources close to the user suggest that there may be diversion from licit
sources or foreign purchase, particularly from Asia.
5. Possible consequences of prohibition
5.1. Legal status
Ketamine is subject to control in five Member States: Belgium, France,
Greece, Ireland (to be scheduled in the Misuse of Drugs Act) and
Luxembourg. It is controlled through general medicines legislation in all
Member States. Due to the fact that ketamine preparations, as medical and
veterinary products, have marketing authorisation in most Member States
and have a recognised unique therapeutic value, the major concern appears
to be diversion from legitimate supply to the black market.
The complex routes of synthesis for illegal manufacturing of ketamine
reduce the potential impact on the illegal market for ketamine of targeted
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measures to control ketamine precursors. Illegal production of ketamine is
unlikely to develop, due to these conditions. However, the implication of
organised crime in the production and supply of ketamine in tablet form,
with the possible health risks associated with sale of ketamine tablets with
ecstasy logos, represents a particular matter for concern.
5.2. Possible consequences of prohibition
The possible consequences of prohibition discussed at the meeting included
the following.
 The EMEA highlighted the fact that changes in the conditions of marketing
authorisations for ketamine containing medicinal products proposed by
the meeting should be dealt with at national level or referred to the
Committee for Proprietary Medicinal Products (CPMP) and the Committee
on Veterinary Medicinal Products (CVMP).
 Introducing penalties for use would be unlikely to deter use in groups
where illegal drugs are already well established.
 Concern was expressed about the effects of prohibition and control measures
on informal information and harm-reduction networks.
 One opinion was that control measures might draw unnecessary attention
to the drug, thus increasing its attractiveness to potential users.
 In discussions on possible mechanisms of control, differences between
control of the bulk drug and of medicinal products containing ketamine
were mentioned. In this regard, there was strong support for the suggestion
that the chemical and pharmaceutical industry should be consulted about
suitable control measures.
 The view that, as a common minimum approach, medicines legislation (4)
should be used as a control measure received strong support.
(4) Legislation such as the EU regulation based upon Council Directive 65/65/EEC of 26 January 1965,
as amended by Directives 83/570/EEC, 87/21/EEC, 89/341/EEC and 93/39/EEC, as well as decisions
of the Court of Justice of the European Communities, especially Case C-112/89.
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 Another opinion expressed at the meeting was that, in addition to existing
medicines legislation, stronger control measures to deal with diversion,
trafficking and inadvertent exposure (i.e. through fake ‘ecstasy’ tablets)
were necessary. It was also felt that such measures are required to control
the import and export of ketamine.
 The meeting noted the concern of the Federation of Veterinarians of
Europe that placing ketamine under the same stringent restrictions as opioids
could be detrimental to good veterinary medicine. It was noted that the
same concern could apply to the use of ketamine in human medicine.
6. Conclusions
The Scientific Committee of the EMCDDA, enlarged with experts from the
Member States and representatives of the Commission, Europol and EMEA,
have considered the health and social risks as well as the possible conse-
quences of prohibition of ketamine and, in accordance with Article 4 of the
joint action, submit the following conclusions:
6.1. Ketamine is not a new synthetic drug. While it has a significant
therapeutic use, it is also being used in recreational settings.
6.2. The meeting noted the main risks of the recreational use of the drug,
such as psychological dependence, loss of self-control and the risk of
acute intoxication. To date, the use of ketamine has been reported as
associated with mortality or morbidity in a small number of cases.
6.3. An opinion which received strong support at the meeting was that, 
as a common minimum, ketamine should be subject to control under
medicines legislation in Member States.
6.4. Another strong opinion expressed at the meeting was that, in addition
to the medicines legislation, stronger control measures to deal with
diversion, trafficking and inadvertent exposure to the drug were necessary.
6.5. The meeting recommends that both the EMCDDA and Europol should
further monitor the manufacture, trafficking, distribution, patterns of use
and health consequences of ketamine, particularly the fatalities and
non-fatal emergencies.
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6.6. The meeting recommends that a study on the possible neurotoxicity of
ketamine in primates should be considered in the context of the fifth
framework research programme of the European Commission.
6.7. The possible options for improving control of diversion should be
discussed with the chemical and pharmaceutical industry in order to
ensure the continued availability of ketamine for medical and veterinary
use.
6.8. The meeting recommends that consideration should be given to how
appropriate information can be disseminated to the most vulnerable risk
groups.
Lisbon, 25 September 2000
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Europol–EMCDDA progress report on 
ketamine in accordance with Article 3 of 
the joint action of 16 June 1997 concerning
the information exchange, risk assessment 
and the control of new synthetic drugs
Introduction
The Horizontal Working Party on Drugs, at its meeting of 22 September
1999, asked the EMCDDA and Europol for preliminary information on the
substance ketamine under Article 3 of the joint action. Europol national units
and Reitox national focal points were subsequently requested to provide
information on ketamine. The EMCDDA and Europol also conducted
enquiries. No reporting took place using the ‘Europol–EMCDDA reporting
form on new synthetic drugs’.
Ketamine is subject to control in five Member States: Belgium (Royal Decree
31.5.1976), Greece (Law 1729/87); France (Decree 8.8.1997); Ireland (to be
scheduled under the Misuse of Drugs Act); and Luxembourg (Grand-Ducal
Decree 4.3.1974). It is controlled through means of medicinal legislation in
Germany, Spain, the Netherlands, Austria, Sweden and the United Kingdom.
In the United Kingdom, the Advisory Council for the Misuse of Drugs
recommended monitoring of ketamine.
Available information on ketamine
Chemical and physical description, including the name 
by which ketamine is known
The chemical name for ketamine is 2-(2-chlorophenyl)-2-(methylamino)-
cyclohexanone.
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Figure 1: Structural formula of ketamine
It is a dissociative anaesthetic drug used as a licensed product in veterinary
medicine (i.e. Vetalar and Imalgene) and to a lesser extent by the medical
profession, mainly for emergency care (i.e. Ketalar). Ketamine is freely soluble
in water or alcohol and usually comes from the pharmaceutical industry in
liquid form in ampoules for intramuscular or intravenous injections.
Ketamine is known in Member States by the street names: K, special K,
vitamine K, ket, super K, liquid E and others (5).
In the United Kingdom, ketamine appears in the form of well-made tablets,
visually similar to and often sold as ‘ecstasy’ tablets. It is rarely found alone
in tablets but is usually mixed with a stimulant drug (e.g. amphetamine or
MDMA, ephedrine and/or caffeine). Typical impressions on the tablets are
the same as those found on ‘ecstasy’ tablets, such as a bird, clover/club,
heart, etc.
Ketamine is also found on the ‘illicit recreational’ drug market as liquid,
powder and capsules, where it is snorted or swallowed. It has also been used
as a cutting agent for drugs such as cocaine, amphetamine and heroin.
Ketamine does not react with commonly used field-test kits (e.g. Marquis
reagent) although other drugs present may produce a positive reaction.
The typical nasal dose is around 200 mg, thus one dose at this price is less
than EUR 3. With ease of access, at relatively low prices, it is unlikely that
O
CI
NH
CH3
(5) However, as occurs with logos, drug users and suppliers in different countries may apply the
same synonym to different drugs, either mistakenly or deliberately. For example, in Australia, ‘liquid
ecstasy’ has been reported to be a synonym for ketamine, whilst in the United Kingdom it is a
synonym for GHB. In the absence of facilities for chemical analysis at user level, the significance
of a logo or a synonym is uncertain with regard to drug content. ‘K hole’ is a term used by conscious
consumers of ketamine to describe and locate the effects of the drug.
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illicit tablet manufacturers would contemplate the synthesis of ketamine,
which is probably too difficult for most clandestine chemists.
Information on the frequency, circumstances and/or quantities in which
ketamine is encountered
In Austria, although there have been no reported seizures or hospital treat-
ment episodes attributed to ketamine, there is some anecdotal evidence of
use among very small, closed groups.
In Belgium, 89 kg of ketamine were seized in September 1999. In January
2000, another seizure of 3 kg took place. Both seizures contained pure
ketamine in powder form. In addition, there have been a few seizures of
ketamine in tablets, mixed with MDMA or amphetamine. Ketamine is not
free for trade in Belgium.
In Finland, there were 14 seizures of ketamine in 1998, totalling 614 tablets.
In 1999, five seizures occurred, totalling 49 tablets with the ‘propeller’ logo.
In France, two seizures of tablets with an ecstasy-type logo containing keta-
mine and amphetamine were reported in 1998 and 1999. A survey of young
people who were regular attendees at techno party events found that 15 %
reported that they had taken ketamine. Among a matched control group of
young people who did not go to such events, consumption of ketamine was
non-existent, indicating that use is not widespread.
In Germany, six people were arrested in May 1999 in relation to the seizure
of an illicit synthetic drug laboratory. A large amount of laboratory equip-
ment was seized, as were chemicals and end products. These included 182 g
of ketamine hydrochloride in tablet form (700 tablets with blue colour) and
0.9 g of ketamine powder. Another 2 000 yellow tablets were seized con-
taining methamphetamine hydrochloride and ketamine hydrochloride.
In Greece, treatment staff and helplines reported three instances of ketamine
use in 1999 in the same recreational drug scene as ecstasy and cocaine.
There are reports of ketamine liquid being boiled to obtain powder that is
sniffed.
In Ireland, from 1 January 1998 to 15 October 1999, there have been 43 incidents
of ketamine seizures. In 40 of these cases, ketamine and ephedrine were present
24
in tablet form (number of tablets 4 500); one case was of 27 000 tablets with
ketamine only or ketamine with caffeine, one case of 26 tablets which con-
tained only ketamine and one case of 0.23 g of ketamine powder. The vast
majority of ketamine seized in Ireland emanates from the Netherlands.
Organised crime groups or Irish nationals are responsible for the importation
and distribution of ketamine. There are no indications that Ireland is a transit
or export point.
In Spain, a combination of ketamine and cocaine is known as ‘special CK’ (6).
Early seizures took place in 1995 in the Balearic Islands and in 1996 a sub-
mission of ketamine mixed with manitol was found in Barcelona. There have
been a series of small seizures throughout 1996 to 1999. Between 1995 and
1996, a British police team visited the Balearic Islands to investigate the origin
of ketamine tablets that had been seized in discotheques and bars and were
suspected to have been manufactured in the United Kingdom. The seizures
were mainly from foreign tourists and none have occurred in Madrid and
other major cities. This, together with the absence of deaths, indicates a lack
of widespread popularity in Spain.
In Sweden, ketamine is an integral ingredient in four different medicinal
products and some years ago stolen ketamine products from the legal phar-
maceutical trade appeared on the illegal market. Misuse is a minor concern
at present. There have been occasional and minor seizures of ketamine on
the domestic user market.
In the United Kingdom, seizures climbed rapidly in the early 1990s. In 1995,
almost 100 000 tablets containing ketamine and ephedrine and carrying a
logo commonly found on ecstasy tablets were seized. During 1995 and
1996, a number of hospitalisation cases were reported. Ketamine seizures
peaked in 1997 and over the past two years have stabilised at around 200
submissions per year. There have been few significant customs seizures, sug-
gesting that most, if not all, tablets consumed in the United Kingdom are pro-
duced there. It is believed that ketamine raw material is imported in bulk
from legitimate suppliers in Europe. Ketamine appears to be distributed
through illicit drug distribution networks. Small quantities can be obtained
by mail order from chemical catalogues at around EUR 64 for 5 g. A num-
ber of ketamine tablet manufacturers have been successfully prosecuted for
(6) Referring to Calvin Klein, the popular American designer.
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conspiracy to supply, or attempt to supply, a controlled drug and some dealers
have been prosecuted for conspiracy to defraud contrary to common law.
Recently, in the north-west of England and in London, it has been reported
that, among some circles of ‘early adopters’ and ‘media types’, ketamine is
being sought out as a drug experience in its own right. In a targeted survey
of 200 regular techno dance clubbers in London in 1998, 40 % said that
they had experimented with ketamine and 10 % were planning to use it that
evening. The survey placed ketamine in fourth place after cannabis, amphet-
amine and ecstasy. More recently, some outreach workers have expressed
scepticism about the existence of a significant trend in ketamine use.
However, considering the perceived influence of the media on patterns of
drug consumption, it is too early to dismiss the development of ketamine use
as a new trend.
A first indication of the possible risks associated with ketamine
Ketamine is not strictly hallucinogenic, but in small doses users feel
detached from their immediate environment. It also causes catalepsis (muscle
rigidity) and reduces reaction to pain. Overdose is rare, but adverse effects
include hypertension, tachycardia, headache, nausea, vomiting, slurring of
speech, numbness and, in more severe reactions, temporary unconsciousness,
respiratory collapse or heart failure. It can also provoke panic or acute
anguish or anxiety, particularly when taken unknowingly or without prior
knowledge of its possible effects. There is also some evidence that the effects
of ketamine are considerably diminished in someone with tolerance.
However, the sudden anaesthetic effects of ketamine create high risk for
accidents and makes driving following consumption dangerous.
Two deaths linked with the use of ketamine were reported for 1996 in
Ireland. Both persons who died had a history of ecstasy use. In one death,
ketamine was found in combination with opiates. In the other it was found
in combination with ephedrine and pseudoephedrine.
During 1995 and 1996, in the United Kingdom, a number of hospitalisation
cases occurred of users suffering anxiety attacks who had taken large doses
of ketamine believing it to be ecstasy. Since 1996, no deaths have been
recorded but there is growing documentation showing similarity to phency-
clidine, associated with foetal malformation (mainly cephalic size reduction)
in pregnant women and effects on neonates.
26
A study of 346 young people attending raves in Vienna found that young
people who were regularly taking ecstasy and amphetamine considered the
psychological risks attached to taking drugs such as ketamine very high.
Information on chemical precursors
The precursors mainly used for illicit production of ketamine are cyclohexa-
none, methylamine and chlorobenzene.
Information on the mode and scope of established or expected use 
of ketamine as a psychotropic substance
Ketamine is often sold in a form which is indistinguishable from ecstasy,
although there are also reports of ampoules, liquid, powder and capsules.
The dose varies depending on the pattern of use and route of administration.
For example, at low doses ketamine is a stimulant, especially if it is sniffed
with amphetamine and/or cocaine or taken with drugs in the ‘illicit recreational’
drug scene. It may also be administered in intramuscular doses for a specific
ketamine experience.
A study of 100 ketamine users conducted by the Australian National Drug
and Alcohol Research Centre in the mid-1990s reported that there appeared
to be four primary user groups:
 injecting heroin users;
 members of the gay scene;
 regular drug users in the ‘dance’ scene; and
 ‘self-exploratory’ people.
There have been no prevalence studies on ketamine use in Europe but there
is little evidence that it is abused on a wide scale. The anaesthetic properties
and unpredictable effects make it an unsuitable drug for widespread ‘going
out’ recreational purposes. These effects distinguish ketamine from MDMA
and are likely to prevent widespread dissemination of illicit ketamine use.
Numerous books and journal articles have been written concerning ketamine.
Information about its effects, supply and health risks are provided on the Internet.
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Information on other use of ketamine and the extent of such use
The role of ketamine in producing psychotherapeutic effects, particularly in
relation to ‘near-death experiences’, is widely documented.
Drafted by Europol and the EMCDDA
17 March 2000
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Use of ketamine in human medicine in the EU
Member States (EMEA)
As part of the EMEA’s preparation for the risk assessment of ketamine, they
asked for information on each national situation regarding the terms of
authorisation and therapeutic value of the product.
Ketamine is authorised in most countries of the EU with similar indications,
except for Greece, where the marketing authorisation was recalled in 1998.
It is indicated for special situations in anaesthesia (alone or in combination)
and for special situations in pain treatment. Its use generally seems to be
limited and decreasing, with the exception of Belgium, where a steady
increase in use has been observed in the last 10 years, and the United
Kingdom, which reported an increase in hospital prescriptions between
1997 and 1999. Although most responses did not contain information as to
whether action has been taken to list the products under the 1971 UN
Convention on Psychotropic Substances, in many countries ketamine is subject
to restricted prescription or regulated as a psychotropic substance.
London, 30 March 2001
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Use of ketamine in veterinary medicine in the
EU Member States (EMEA)
In September 2000, the EMEA Veterinary Unit Secretariat was requested by
the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)
to provide information in order that the health and social risks as to the
possible consequences of prohibition of ketamine could be assessed. This
was to be considered at a meeting to be held in Lisbon, Portugal, on 25 and
26 September 2000. As ketamine is not a centrally authorised product under
the terms of Council Regulation (EEC) No 2309/93, the EMEA undertook to
consult with the competent authorities for veterinary medicinal products in
the Member States as to the authorisation status of this product at national
level and sought detailed information on its use and value as a veterinary
medicinal product for veterinary practitioners in the European Union. As a
result of that consultation, through the Veterinary Mutual Recognition
Facilitation Group of the European Union and an in-depth review with 
the Federation of Veterinarians of Europe (FVE), the following points can be
concluded about the use of ketamine in veterinary practice in Europe.
Ketamine constitutes an essential medicine for the veterinary profession in the
EU today. It is widely used for anaesthesia and analgesia by the veterinary
profession. Ketamine is an essential anaesthetic for veterinary use, because
it is the only injectable anaesthetic that is safe, well established and well
tolerated among the full range of species that the veterinarians are called
upon to treat. These include both large and small domestic animals, children’s
pets and laboratory animals, large, wild and zoo animals, as well as birds
and reptiles. It has been used safely by virtually every veterinary practice
throughout Europe and on a global basis under prescription-only medicine
conditions for many years.
Whilst the veterinary profession also uses pure µ-opioid analgesics, in most
countries these are kept under very tightly controlled conditions, locked in 
a dedicated cupboard with only veterinary access, their use recorded very
precisely. There is no doubt that pure µ-agonists are not used as often as
good anaesthetic and analgesic practice would indicate, because they are
controlled under such tight restrictions. It would therefore be very detrimental
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to good veterinary practice if ketamine also had to be kept under such stringent
restrictions. On welfare grounds alone, it is essential that the veterinary
profession is able to use such an agent easily on a daily basis and in field
situations where inhalation anaesthesia is not possible.
London, 28 May 2001
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Review of the pharmacotoxicological data 
on ketamine (2-(2-chlorophenyl)-2-
(methylamino)-cyclohexanone) (7))
This report was commissioned by the EMCDDA as part of a risk assessment
on the drug ketamine in accordance with Article 4 of the joint action con-
cerning the information exchange, risk assessment and control of new syn-
thetic drugs adopted by the Council of the European Union on 16 June 1997.
This report summarises the relevant data required by the Technical Annexes
A and B of the guidelines for the risk assessment of new synthetic drugs, as
adopted by the Scientific Committee of the EMCDDA.
Introduction
The anaesthetic ketamine was first synthesised by Calvin Stevens at Parke-
Davis laboratories in 1962 (Jansen, 2000a) and patented in Belgium in 1963
and in the US in 1966 (Budavari et al., 1989). Ketamine was first marketed
in the early 1970s (FDA, 1979) and promoted as a more acceptable alternative
to its congener, PCP (‘angel dust’; Dotson et al., 1995). PCP was abandoned,
except for veterinary use, because of its adverse effects, such as hallucina-
tions and delirium. Although ketamine is not devoid of similar side-effects,
these are less persistent, and ketamine has now achieved a unique place in
medical practice. PCP had become popular as a recreational drug in the
1960s and had caused considerable problems as such. Ketamine abuse was
first noted on the west coast of the United States in 1971 (Siegel, 1978). In
the early 1990s in the United Kingdom, several reports of more widespread
recreational use of ketamine appeared (Hall and Cassidy, 1992; McDonald
and Key, 1992; Jansen, 1993; Dalgarno and Shewan, 1996). An inquiry by
the EMCDDA has shown that recreational use of ketamine is noted in other
Member States as well (e.g. Arditti, 2000).
(7) This report was written by L.A.G.J.M. van Aerts and J.W. van der Laan of the Laboratory for 
Medicines and Medical Devices, National Institute of Public Health and Environment, the Netherlands.
Valuable help and advice was contributed by Dr Peter Kasper of the Federal Institute for Drugs and
Medical Devices, Berlin, Germany.
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Since ketamine has existed for 37 years as a chemical entity, it is difficult 
to call it a new synthetic drug. Ketamine cannot be considered a drug with
limited therapeutic value, as its pharmacological properties have given it a
unique place in human and veterinary medical practice. Nevertheless, in
light of its current use as a recreational drug in the EU, the Portuguese
Presidency, on behalf of all Member States and in the framework of the
Horizontal Working Party on Drugs of the Council of the European Union,
formally referred the substance ketamine (2-(2-chlorophenyl)-2-(methylamino)-
cyclohexanone) to the EMCDDA for a risk assessment under Article 4 of the
joint action concerning the information exchange, risk assessment and control
of new synthetic drugs adopted by the Council of the European Union on 
16 June 1997, on the basis of Article K3 of the Treaty on European Union.
This report summarises the relevant data required by the Technical Annexes
A and B of the principles for risk assessment of new synthetic drugs, as
adopted by the Scientific Committee of the EMCDDA.
Pharmacotoxicological evidence
Chemical information
Ketamine (2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone), an arylcyclo-
alkylamine, is structurally related to phencyclidine (PCP) and cyclohexa-
mine. Ketamine hydrochloride is a water-soluble white crystalline and has a
pKa of 7.5 (Budavari et al., 1989). Its free base, ketamine, has a lipid solubility
10 times that of thiopentone. It contains a chiral centre at the C-2 carbon of
the cyclohexanone ring, so that two enantiomers exist, S-(+)-ketamine and
R-(-)-ketamine. Ketamine is used in human and veterinary medicine as an
anaesthetic and analgesic. The commercially available pharmaceutical form is
an aqueous solution for injection of the racemic mixture of the hydrochloride
salt. Clinically, ketamine usually is administered intravenously or intramus-
cularly. Recreationally, ketamine is taken intranasally, orally, intramuscularly,
subcutaneously or intravenously. Typical recreational doses are 75–125 mg
intramuscularly or subcutaneously, 60–250 mg intranasally, 50–100 mg
intravenously and 200–300 mg orally. Doses may vary considerably,
depending on the strength of the effect desired, differences in sensitivity and
development of tolerance.
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Chemical description (including methods of synthesis, precursors,
impurities if known, type and level)
The chemical names used for ketamine are:
 ketamine;
 ketamine hydrochloride;
 2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone hydrochloride;
 2-(o-chlorophenyl)- 2-(methylamino)-cyclohexanone hydrochloride;
 2-(methylamino)-2-(2-chlorophenyl)-cyclohexanone hydrochloride;
 2-(methylamino)-2-(o-chlorophenyl)-cyclohexanone hydrochloride;
 cyclohexanone, 2-(2-chlorophenyl)- 2-(methylamino) hydrochloride;
 cyclohexanone, 2-(o-chlorophenyl)- 2-(methylamino) hydrochloride;
 CI-581;
 CL-369;
 CN-52,372-2.
The chemical formula for ketamine is:
Free base C13H16ClNO
Hydrochloride salt C13H17Cl2NO
The molecular structure is shown in Figure 2.
Figure 2: Molecular structure of ketamine
Ketamine PCP
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Ketamine contains a chiral centre at the C-2 carbon of the cyclohexanone
ring, so that two enantiomers exist: S-(+)-ketamine and R-(-)-ketamine.
The CAS number for ketamine is:
Free base 6740-88-1
Hydrochloride salt 1867-66-9 (current); 81771-21-3, 96448-41-8, 42551-
62-2 (previous)
The molecular weight of ketamine is:
Free base 237.73
Hydrochloride salt 274.18
1.15 mg of the hydrochloride salt is equivalent to 1 mg of the free base.
The melting point of ketamine is:
Free base 92–93 °C
Hydrochloride salt 262–263 °C
The proprietary names used for ketamine are:
Ketalar, Ketolar, Ketaject, Ketanest, Ketaset, Ketavet, Ketavet 100, Ketalin,
Vetalar, Kalipsol, Calipsol, Substantia, Ketamine Panpharma, Ketamine UVA,
Chlorketam, Imalgene (Budavari et al., 1989; Reynolds et al., 1989; Arditti,
2000).
The most common street names for ketamine currently in use in the EU are
ketamine, K, ket, vitamin K, special K and super K (Jansen, 1993;
Europol/EMCDDA, 2000). Liquid E, a name more often used for GHB
(gamma-hydroxybutyric acid), was mentioned as well (Europol/EMCDDA,
2000). Additionally, the French assessment report on ketamine (Arditti,
2000) mentions kéta K, kit kat, cat valium, flatliners (also in use for 4-MTA),
kaddy, kate, tac et tic, liquid G and spécial la coke. Other names that were
reported earlier in the United States are kay, jet, super acid, 1980 acid,
special LA coke, super C, purple, mauve and green (FDA, 1979; Felser and
Orban, 1982).
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Synthesis, precursors, excipients and impurities of ketamine
Ketamine is manufactured by the pharmaceutical industry. The preparation
is described by Stevens, Belgian patent 634208 (1963), which corresponds
to the US patent 3254124 (1966 to Parke-Davis). The synthesis of the optical
isomers is described by Hudyma et al., German patent 2062620 (1971 to
Bristol-Myers) (Budavari et al., 1989).
Ketamine that is used recreationally is mostly diverted from the pharmaceutical
supply to hospitals, veterinary clinics or the pharmaceutical distribution
network. The precursors that are mainly used for its illicit production are
cyclohexanone, methylamine and chlorobenzene (Europol/EMCDDA,
2000). Sources on the Internet rate the synthesis of ketamine as difficult. 
A specific route described on rhodium.lycaeum.org involves the precursors
cyclopentyl bromide, o-chlorobenzonitrile and methylamine. Several addi-
tional reagents and solvents are needed for the four-step synthesis described.
The same site mentions that two ketamine analogues have been found on the
black market: the compound missing the 2-chloro group on the phenyl ring,
and its N-ethyl analogue. According to this Internet site, both of these com-
pounds are considered to be more potent and longer lasting than ketamine.
Using the same synthesis route as described for ketamine, the precursors
benzonitrile and ethylamine would be involved instead of o-chlorobenzonitrile
and methylamine.
Ketamine prepared by the pharmaceutical industry meets the standards of
good manufacturing practice (GMP), which means that the quality and purity
is guaranteed. Ketamine is sold as hydrochloride salt in an aqueous solution
and is packaged in small sealed glass vials. A preservative may also be present.
When the drug is diverted for recreational use, the original pharmaceutical
form is often abandoned. Most users dislike using needles, and the most pop-
ular medium for ketamine is powder form, which is snorted. The powder is
prepared by evaporation of the original solution. This powder is usually sold
in small plastic or paper bags. The ketamine in these bags may be mixed
with other drugs or inactive components. As the effects of ketamine are dose-
dependent, the uncertainty about the concentration of ketamine in the powder
poses a risk for overdosing.
Ketamine can also be administered intranasally by transferring the ketamine
solution to a vaporiser, or it may be presented in tablet form, to be taken orally.
Again, the concentration and presence of adulterants are mostly unknown.
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Tablets containing ketamine are often sold as ‘ecstasy’. Other substances
reported to be present in ketamine-containing tablets are pseudoephedrine,
ephedrine, caffeine, amphetamine, methamphetamine and MDMA.
Legitimate uses of the product
Ketamine hydrochloride is used as an analgesic and anaesthetic in human
and veterinary medicine, where it has acquired a unique place. Important
clinical applications are brief procedures in paediatric and ambulatory
anaesthesia, the treatment of burning-wound patients, use in obstetrics and
for the induction and maintenance of anaesthesia in hypovolemic pericardial
tamponade, constrictive pericarditis and cardiogenic shock patients (Reich
and Silvay, 1989; Haas and Harper, 1992; Bergman, 1999).
According to the information provided by the EMEA on current use in the EU,
it appears that, in general, medicinal use of ketamine for humans is limited.
Its use is considered useful in special circumstances. Italy had no difficulty
in finding alternatives to ketamine. In Germany, S-ketamine has been
licensed as an anaesthetic in human medicine since 1997.
According to the information provided by the EMEA, the use of ketamine in
veterinary anaesthesia, especially in small animals, as well as in exotic animals,
is currently widespread in the EU. Several Member States (Denmark,
Germany, Portugal, Sweden) indicate that ketamine is indispensable in
veterinary medicine in those countries.
Outside the EU, the use of ketamine as an anaesthetic in human medicine
may have a more prominent place in Third World countries, where facilities
are much poorer. Its ease of use gives ketamine a major advantage under
such difficult circumstances (Green et al., 1996).
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Figure 3: Ketamine vials and bags containing ketamine powder
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The pharmaceutical form of the preparations used in medicine is an
injectable solution of the racemic mixture of ketamine hydrochloride in
water (10, 50 or 100 mg/ml). The solution is packaged in small sealed glass
vials.
On the street, ketamine has appeared in various forms. These may be the original
vials containing the ketamine solution, or as a vaporiser, a powder (in bags
or in ampoules) or in tablets.
In powder form, combination with cocaine has been observed (CK, or Calvin
Klein). In tablet form, mixtures of ketamine and a range of other substances
have been reported, including pseudoephedrine, ephedrine, caffeine, amphet-
amine, methamphetamine and MDMA. The ketamine content of three
tablets in which ketamine was quantified by a Dutch drug supply monitor
varied from 89 to 114 mg. In these tablets, methamphetamine (6 and 11 mg),
caffeine (31 and 55 mg) and ephedrine were also found.
Routes of administration
Clinically, the drug is usually administered by intramuscular or intravenous
injection. For analgesia, the intrathecal route is used as well. Administration
by the oral and rectal routes has also been reported (Reich and Silvay, 1989).
When ketamine is used recreationally or experimentally, the most popular
route of administration is the intranasal route (i.e. snorting the powder or
inhaling a solution from a vaporiser). Some long-term users may use the
Pharmaceutical form (powder, capsules, tablets, liquid, injectables, cigarettes)
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intramuscular, subcutaneous or intravenous route as well. All routes of
administration that involve the use of needles bear the risk of transmitting
diseases like HIV or hepatitis if the needle or syringe is not clean. In the rave
scene, oral administration of ketamine-containing tablets occurs as well.
These may be sold as ecstasy tablets, which poses a risk of inadvertent use
of ketamine by someone expecting to use MDMA.
Dosages by all routes of administration
A dose equivalent to 2 mg of ketamine per kg of body weight given intravenously
over 60 seconds usually produces surgical anaesthesia within 30 seconds
lasting for 5 to 10 minutes (the dose may range from 1 to 4.5 mg/kg). An
intramuscular dose equivalent to 10 mg per kg of body weight (ranging from
6.5 to 13 mg/kg) usually produces surgical anaesthesia within 3 to 4 minutes
lasting for 12 to 25 minutes (Reynolds et al., 1989).
Intravenous administration of 0.2–0.75 mg/kg of ketamine produces analgesia
(Reynolds et al., 1989). Using the oral or intramuscular route, a dosage of
0.5 mg/kg induces analgesia (Grant et al., 1981). Although the time differs,
depending on the route, the similarity of the dosages to obtain analgesia
using different routes might be explained by the analgesic properties of the
primary metabolite norketamine (Reich and Silvay, 1989).
Subanaesthetic intravenous doses inducing psychotropic effects range from
0.1 to 1.0 mg/kg. In clinical studies, this dose may be divided into a bolus of
0.1–0.2 mg/kg and a maintenance infusion of 0.0025–0.02 mg/kg/min
(Krystal et al., 1994; Malhotra et al., 1996; Engelhardt, 1997; Vollenweider
et al., 1997; Oranje et al., 2000).
Intramuscular administration of ketamine in a dose ranging from 25 to 200 mg
has been reported to produce psychotropic effects in humans (Hansen et al.,
1988).
Recreational users who snort the powder describe the dose as a ‘typical line’,
suggesting a quantity between 60 and 250 mg (Dalgarno and Shewan, 1996).
Malinovsky et al. (1996) found that bioavailability of nasally administered
ketamine in children was approximately 50 %, whereas bioavailability of
intramuscularly administered ketamine is approximately 93 % (Grant et al.,
1981). The dose range for intranasally administered ketamine is, therefore,
probably higher than that for the intramuscular route.
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Bioavailability is low when ketamine is administered orally (see the section
‘Pharmacokinetics’, page 42). The main active metabolite, norketamine,
which has a potency one third of the parent compound, predominates after
oral administration. Consequently, oral dosages are larger than those admin-
istered by other routes (typical doses may be expected to be around 200–300 mg).
Besides the route dependency of the dose needed to evoke psychotropic
effects, the dose will vary among users, depending on the strength of the
effect desired, differences in sensitivity and development of tolerance.
Commonly, users titrate the quantity individually to achieve the desired
effects.
Toxicology and pharmacology in animals and humans
Pharmacodynamics
A large body of literature exists on the neuropharmacological properties of
ketamine. These studies were performed both in vitro and in vivo. The main
characteristics of ketamine’s action on the central nervous system will be
summarised in this section.
Ketamine is a dissociative anaesthetic (Domino et al., 1966). Originally, the
dissociation component referred to a functional and electrophysiological
dissociation of thalamoneocortical and limbic systems (Reich and Silvay,
1989; Haas and Harper, 1992). More recently, the nature of the subanaes-
thetic ketamine experience has led to the use of the term ‘dissociative’ in a
more psychological sense, referring to a feeling of dissociation of the mind
from the body (Jansen, 1990, 2000a).
Ketamine binds to the so-called PCP-binding site, which is a separate site of
the NMDA-receptor complex located within the ion channel, thereby blocking
the transmembranous ion flux. This makes ketamine a non-competitive
NMDA-receptor antagonist. NMDA-receptors are calcium-gated channel
receptors. The endogenous agonists of the receptor are the excitatory amino
acids glutamic acid, aspartic acid and glycine. Activation of the receptor
results in opening of the ion channel and depolarisation of the neurone. The
NMDA-receptor is involved in sensory input at the spinal, thalamic, limbic
and cortical levels. Ketamine would be expected to block or interfere with
sensory input to higher centres of the CNS, with the emotional response to
these stimuli and with the process of learning and memory (Bergman, 1999).
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Awakening from ketamine anaesthesia takes place at plasma concentrations
of 0.064 to 1.12 µg/ml (Reich and Silvay, 1989). Psychotropic effects have
been described when plasma concentrations range from 0.05 to 0.3 µg/ml
and with regional brain concentrations higher than 0.5 µg/ml (Hartvig et al.,
1995; Bowdle et al., 1998; Oranje et al., 2000).
Several studies indicated that opioid receptors are also involved and that 
the analgesic effect of ketamine may largely be attributed to the activation 
of these central and spinal receptors. The plasma levels at which analgesia
is achieved are 0.15 µg/ml following intramuscular administration and 
0.04 µg/ml after oral administration. This difference may be explained by a
higher norketamine concentration due to first-pass metabolism. This main
metabolite apparently contributes to the antinociceptive effect (Shimoyama
et al., 1999).
Some of the effects of ketamine may be due to its actions on catecholamine
systems, notably an enhancement of dopamine activity (White and Ryan,
1996; Smith et al., 1998; Vollenweider et al., 2000). A series of experiments
by Hancock and Stamford (1999) on the effects of ketamine on uptake and
efflux of dopamine in the rat nucleus accumbens (NAc) led the authors to
conclude that ketamine increases NAc dopamine efflux not by block of
dopamine uptake, autoreceptors or NMDA receptors, but by mobilisation of
the dopamine storage pool to releasable sites. In the rat, it has been shown
that repeated ketamine administration diminished the initial five-fold
increase in dopamine release in the prefrontal cortex, whereas the increase
in extracellular 5-hydroxyindole acetic acid (5-HIAA, a serotonin metabolite)
levels is enhanced. This suggests that the balance between dopamine and
serotonin neurotransmission in the prefrontal cortex is altered after repeated
exposure to ketamine (Lindefors et al., 1997). The dopaminergic effects 
may be of relevance for the euphorigenic, addictive and psychotomimetic
properties of ketamine.
Other neuropharmacological actions are an agonistic effect on α- and -
adrenergic receptors, an antagonistic effect at muscarinic receptors of the
CNS and an agonistic effect at the σ-receptor (Bergman, 1999).
The principal metabolite, norketamine, is pharmacologically active. Its bind-
ing affinity to the NMDA-receptor and its anaesthetic properties are approx-
imately one third of the parent compound contributing significantly to the
analgesic effect of ketamine (Shimoyama et al., 1999).
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The commercially available ketamine is a racemic mixture of two enantiomers.
The S-enantiomer is shown to be the more potent one, with an approxi-
mately three- to fourfold anaesthetic potency compared to R-ketamine. This
correlates to the higher binding affinity for the PCP site of the NMDA-receptor.
The psychotomimetic properties of ketamine are mainly caused by the 
S-enantiomer, although subanaesthetic doses of R-ketamine may induce a
state of relaxation (Engelhardt, 1997; Vollenweider et al., 1997).
Secondary pharmacology
EFFECTS ON THE CARDIOVASCULAR SYSTEM
Ketamine differs from most anaesthetic agents in that it appears to stimulate
the cardiovascular system, producing changes in heart rate, cardiac output
and blood pressure (Haas and Harper, 1992). The mechanism is not well
understood, although elevated levels of circulating catecholamines due to
reduced re-uptake may contribute to this phenomenon. On the other hand,
cardiodepressant effects have been noted in critically ill patients. This may
be due to chronic catecholamine depletion preventing any sympathomimetic
effects of ketamine and unmasking a negative inotropic effect which is usually
overshadowed by sympathetic stimulation (Reich and Silvay, 1989; White
and Ryan, 1996). The cardiovascular effects of ketamine usually do not pose
a problem, but its use is contraindicated in patients with significant
ischaemic heart disease and should be avoided in those with a history of
high blood pressure or cerebrovascular accidents (Haas and Harper, 1992).
In recreational ketamine users, presenting to an emergency hospital depart-
ment, tachycardia was the most common finding upon physical examination
(Weiner et al., 2000).
EFFECTS ON THE RESPIRATORY SYSTEM
Ketamine is a mild respiratory depressant. Depending on dose, it causes a
shift of the CO2 dose-response curve to the right but does not change the
slope of the curve. Respiratory drive to CO2 may be depressed by as much
as 15 to 22 %. This effect is similar to that of opioids but different to most
sedative hypnotics and anaesthetics, suggesting that opioid receptors may
play a role in the respiratory depressant effect. In clinical studies, these
effects were observed only at high doses. Some case reports describe respi-
ratory depression after rapid intravenous injection, but also after routine
paediatric use of ketamine administered intramuscularly (Reich and Silvay,
1989; White and Ryan, 1996). It appears that respiratory depression is not
likely to occur at recreational doses, but it cannot wholly be excluded.
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Ketamine has a bronchodilatory effect, but pharyngeal and laryncheal reflexes
are maintained (Reich and Silvay, 1989).
OTHER PHARMACOLOGICAL EFFECTS
Other pharmacological effects that have been noted are as follows:
 ketamine increases muscle tone (Reich and Silvay, 1989);
 blood glucose and plasma cortisol and prolactin are increased after keta-
mine administration (Reich and Silvay, 1989; Krystal et al., 1994); and
 ketamine may decrease intraocular pressure (Reich and Silvay, 1989).
Pharmacokinetics
The pharmacokinetics of ketamine have been studied in humans (e.g. Grant
et al., 1981; Clements et al., 1982; Malinovsky et al., 1996). The reported
volumes of distribution varied from 1.5 to 3.2 l/kg. The clearance was 
in the range 12–28 ml/kg/min. The volume of distribution and clearance for
S-ketamine are 9 and 14 % greater than those for R-ketamine (Engelhardt, 1997).
ABSORPTION
Ketamine is rapidly absorbed when administered through the intramuscular
(Tmax 5–15 min.), nasal (Tmax 20 min.) or oral route (as a solution; Tmax 30
min.). The bioavailability is low when ketamine is given orally (17 %) or rec-
tally (25 %). Extensive first-pass metabolism in the liver and intestine is large-
ly responsible for this effect. Bioavailability after nasal administration is
approximately 50 % (Malinovsky et al., 1996). The lower bioavailability
with this route compared to the intramuscular route may partly be caused by
swallowing significant amounts of the intranasal deposit.
DISTRIBUTION
Initially, ketamine is distributed to highly perfused tissues, including the
brain, to achieve levels four to five times those in plasma (distribution half-
life after i.v. 24 sec). CNS effects subside, following redistribution to less
well-perfused tissues (redistribution half-life 2.7 min). Ketamine has a high
lipid solubility and low plasma protein binding (12 %), which facilitates
rapid transfer across the blood–brain barrier.
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BIOTRANSFORMATION
Biotransformation primarily takes place in the liver. The most important
pathway is N-demethylation to norketamine. When administered orally or
rectally, initial plasma norketamine concentrations are higher than those 
of ketamine, but the plasma area under the curve (AUC) for norketamine is
similar for all routes of administration. Norketamine has one third the anaes-
thetic potency of ketamine and has analgesic properties. Norketamine may
be metabolised through multiple pathways, but the majority is hydroxylated
and subsequently conjugated.
ELIMINATION
The predominant route of elimination is by liver metabolism. The high
extraction rate (0.9) makes ketamine clearance susceptible to factors affecting
blood flow. The conjugated hydroxy metabolites are mainly excreted renally.
Reported terminal elimination half-lifes were in the range of 100 to 200 minutes.
Toxicology
The clinical safety profile of ketamine is largely based on extensive clinical
experience. The preclinical data may therefore be of less importance for
clinical safety. However, unlike recreational use, long-term clinical use of
ketamine is rare. Therefore, some preclinical data may be of greater impor-
tance for the recreational drug user than for clinical practice.
SINGLE-DOSE TOXICITY
Single-dose acute toxicity shows an LD50 of between 140 (intraperitoneally
in the neonatal rat) and 616 mg/kg bw orally in the mouse (EMEA, 1997). In
adult mice and rats LD50 values were 224 ± 4 mg/kg and 229 ± 5 mg/kg,
respectively (route not indicated) (Budavari et al., 1989).
In squirrel monkeys (Greenstein, 1975), doses above 25 mg/kg administered
intravenously caused anaesthesia. Return of righting reflex as a function of
the dose administered is shown in the graph in Figure 4.
44
Figure 4: Return of the righting reflex in squirrel monkeys
At the highest concentration tested (350 mg/kg), four out of five monkeys
died. In humans, the lowest recommended intravenous dose to induce
anaesthesia is 1 mg/kg. Applying the same ratio of minimal anaesthetic dose
to highest non-lethal dose to humans implies that doses above 11.3 mg/kg
administered intravenously may be lethal in humans. For a person of 60 kg,
this is equivalent to intravenous doses above 680 mg. This estimate is based
on an experiment with a low number of animals and interindividual and
interspecies differences may exist. For these reasons such estimates always
hold some uncertainty and have to be regarded with caution. Yet, considering
data from case reports of fatal ketamine intoxications in humans, this esti-
mate seems to be a realistic one (see Table 1).
Several studies investigated the local tolerance of ketamine when administered
intrathecally (e.g. Malinovsky et al., 1996; Errando et al., 1999). Ketamine,
when injected without preservative, did not cause neurotoxicity in the spinal
cord of swine or rabbits. However, when combined with the preservatives
benzethonium chloride or chlorobutanol, it caused discrete histopathological
changes in swine and rabbits.
NEUROTOXICITY
One issue that has been investigated in animals, but that has received little
attention in the clinical literature and may be of importance for the recre-
ational user of ketamine, is the neurotoxicity as observed in rats (Olney et
al., 1989, 1991). When administered subcutaneously, ketamine (40 mg/kg)
caused vacuolisation in posterior cingulate and retrosplenial cerebrocortical
neurones in the rat. Lower doses (≤ 20 mg/kg) did not cause such pathological
changes. These highly localised neurotoxic effects have also been shown for
other NMDA-antagonists (PCP, tiletamine, MK-801; Olney et al., 1989,
1991; Auer, 1994; O’Callaghan, 1994).
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It has been suggested that the mechanism for this neurotoxic response is
based on an NMDA-antagonist-mediated hypofunction of the NMDA-receptor
resulting in a combination of enhancement of excitatory neuronal pathways
and inhibition of inhibitory neuronal pathways that lead to and from specific
groups of neurones in the cingulate and retrosplenial cerebral cortices.
Consistent with this hypothesis, it has been shown that several classes of
drugs effectively inhibit the neurotoxic effects of the NMDA antagonists,
including:
 muscarinic receptor antagonists;
 GABAA-receptor agonists (benzodiazepines and barbiturates);
 σ-receptor antagonists;
 non-NMDA (kainic acid) receptor antagonists;
 α2-adrenergic receptor agonists;
 certain typical antipsychotic agents (haloperidol, thioridazine, loxapine); and
 atypical antipsychotic agents (clozapine, flupefiapine, olanzapine)
(Bergman, 1999).
It may be anticipated that substances with opposite pharmacological actions
to those classes of drugs mentioned here may enhance the neurotoxicity of
ketamine (and related NMDA antagonists). In this context, the following sub-
stances from the recreational drug repertoire should be mentioned: Amanita
muscaria mushrooms (muscarinic agonist), alcohol (NMDA- and partial
GABAA-antagonist), yohimbine (α2-adrenergic receptor antagonist) and other
dissociative drugs (NMDA-antagonists) like PCP and tiletamine.
There may be several reasons why these findings in rats have not led to the
clinical use of ketamine being abandoned. Firstly, ketamine is generally
accepted as a safe anaesthetic without long-term adverse effects (Shorn and
Whitwam, 1980; Reich and Silvay, 1989). Therefore, the preclinical data are
considered to be of limited clinical relevance. Secondly, benzodiazepines
are usually co-administered with ketamine to reduce the occurrence of
emergence phenomena. Benzodiazepines have been shown to protect
against the ketamine-induced neurotoxicity in rats.
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On the other hand, there may be reasons why the findings on the neurotox-
icity of ketamine in the rat may be of concern to recreational users of keta-
mine. Firstly, drug users do not take ketamine in combination with protective
agents like benzodiazepines. Moreover, compounds increasing the neuro-
toxic potency of ketamine may be co-administered. Secondly, recreational
use implies repeated exposure, whereas clinical use is mostly incidental.
Long-term adverse effects in long-term users of ketamine have been reported,
however such data are scarce. Long-term effects that have been noted
include persistent impairment of attention and recall and a subtle visual
anomaly (Jansen, 1990). A review on the Internet (White, 1998) summarises
reports from heavy users of ‘dissociatives’ (i.e. dextromethorphan, ketamine
and PCP). Effects after frequent use that are mentioned include ‘jolts’ or
‘shocks’ when moving the eyes, sharply impaired visual tracking, impaired
recognition of metaphor, impaired language skills and memory problems.
The author relates these adverse effects (that fade with time) to malfunction
of or damage to the cingulate and retrosplenial cortices. To date, there is
insufficient evidence to prove such a relationship in humans. Also, such
Internet reports are bound to be heavily confounded by self-selection bias,
and it is impossible to narrow down the reported effects to a specific drug,
as many subjects are polydrug users.
REPEATED-DOSE TOXICITY
In a toxicological repeated toxicity study carried out on dogs, three groups
of four animals were given daily intramuscular doses of 4, 20 or 40 mg/kg of
body weight over six weeks. At all dose levels there was some degree of
weight loss and anorexia. Some blood parameters were also dose-related
elevated. Histological changes in the liver were minor (EMEA, 1997).
In rats, daily intravenous doses of 2.5, 5 or 10 mg/kg of body weight over six
weeks provoked a slight but not significant decrease in food intake and a
moderate depression in weight gain (EMEA, 1997).
REPRODUCTION FUNCTION
Rats were injected during the premating period (10 mg/kg of body weight
intravenously on days 9, 10 and 11 prior to mating). No effect on litter size
was observed (EMEA, 1997).
EMBRYO-FOETAL AND PERINATAL TOXICITY
Studies were conducted on the teratological effects of ketamine hydrochloride
(25, 50 or 100 mg/kg/day) in rats (Kochhar et al., 1986). Ketamine treatment
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had no significant effect on the number of animals per litter. The histological
examination showed focal nuclear hypochromatosis and interfibrillary oedema
of the heart, diffuse hemopoietic cell infiltration and parenchymal cell
degeneration in the liver, and proximal convoluted tubule degeneration in
the kidney. These degenerative effects were dependent upon the dose and
the duration of treatment (days 1–15 or days 5–15 of gestation). The doses
applied in this study are in the subanaesthetic range in rats (Hammer and
Herkenham, 1983).
In another study in rats, doses (in mg/kg of body weight) 10 times the dose
administered to humans for anaesthesia did not result in teratogenic effects
(El-Karim and Benny, 1976).
When rats were treated on days 7 and 8 of gestation with a ketamine dose
of up to 200 mg/kg, no disorders in the pregnancy course and the embryonic
development were induced (Bandazhevskii and Shimanovich, 1991). At the
administration of a dose of 40 mg/kg on days 11, 13 and 15 of pregnancy,
ketamine was shown to exert a marked embryolethal action and administration
of doses of 20 and 40 mg/kg on days 7, 9 and 11 of pregnancy increased the
number of foetuses with haemorrhages in the internal organs.
Abdel-Rahman and Ismail (2000) studied the teratogenic potency of ketamine
hydrochloride in CF-1 mice with and without cocaine. It was shown that
ketamine (50 mg/kg/day) potentiated the teratogenic effects of cocaine 
(20 mg/kg/day) but was not teratogenic on its own. Considering the higher
metabolic rate of mice, the authors stated that the doses applied were com-
parable to those used by addicted humans and should be toxic to first-time
users. In the absence of toxicokinetic data expressing systemic exposure,
such estimations should be considered rough approximations.
A reproduction study in nine female dogs injected with 25 mg/kg of body
weight intramuscularly six times during one trimester of pregnancy (twice a
week over a three-week period) did not appear to show adverse effects on
the bitch or the pups (EMEA, 1997).
Rats and rabbits were injected during the three fundamental periods of the
reproduction process:
 the premating period (rats 10 mg/kg bw intravenously on days 9, 10 and
11 prior to mating);
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 the period of organogenesis (rats and rabbits 20 mg/kg of body weight
intramuscularly on days 6–10);
 day 11–perinatal period (rats 20 mg/kg of body weight intramuscularly on
days 18–21 of gestation).
For all these groups, there were no significant differences in litter size and
delivered pups (EMEA, 1997). These studies, cited from the CVMP
(Committee on Veterinary Medicinal Products) summary report, have limited
value, since the duration and level of exposure do not meet current standards
of toxicity testing. Thus, possible effects may have gone undiscovered.
Olney and co-workers (2000) have suggested that ketamine has the potential
to delete large numbers of neurones from the developing brain by a mechanism
involving interference in the action of neurotransmitters (glutamate and
gamma-amino butyric acid (GABA) at N-methyl-d-aspartate (NMDA)) and
GABAA receptors (see the section ‘Neurotoxicity’, page 44) during the synap-
togenesis period, also known as the brain growth-spurt period. Transient
interference (lasting ≥ 4 hr) in the activity of these transmitters during the
synaptogenesis period (the last trimester of pregnancy and the first several
years after birth in humans) causes millions of developing neurones to com-
mit suicide (death by apoptosis). Further research will be required to fully
ascertain the nature and degree of risk posed by exposure of the developing
human brain to ketamine.
No data on human pregnancies exposed to ketamine exist (Friedman, 1988),
with the exception of the obstetric use of ketamine during parturition, where
it has been shown that ketamine may depress foetal functions when 2 mg/kg
is administered intravenously to the mother.
In summary, at doses 10 times those used in humans for anaesthesia,
histopathological changes in rat foetuses have been observed. These effects
are dependent on the period of exposure. Based on these preclinical data, in
the absence of sufficient toxicokinetic data in animals, and considering that
rodents have a higher metabolic rate and doses administered were in the
subanaesthetic range in these animals, it cannot be excluded that ketamine
in (sub)anaesthetic doses may adversely affect pregnancy outcome in
humans. However, no data on human pregnancies exposed to ketamine
were found.
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MUTAGENIC AND CARCINOGENIC POTENTIAL OF KETAMINE
Bacterial tests: Ketamine was tested in a limited Ames test using two salmo-
nella strains (TA98 and TA100) and one high test concentration (10 mg/plate)
only. The experiments were done in the presence and absence of rat liver 
S9 mix and showed a negative result (Waskell, 1978).
In another bacterial test, ketamine was tested for its ability to inhibit growth
of three bacterial strains with decreased capacity to repair damaged DNA.
No inhibition of growth of DNA-repair deficient strains relative to a strain
with normal DNA-repair was observed, indicating that ketamine did not
induce DNA damage under the test conditions used (Waskell, 1978).
Mammalian cell tests in vitro: Using an SCE test on CHO cells, ketamine at
concentrations of 1.19, 2.38 and 3.66 mg/l was found to induce an increase
in SCE/cell in a concentration-dependent manner (Adhvaryu et al., 1986).
The highest effect (11.20 SCE/cell at 3.66 mg/l) was less than a doubling of
the control value (7.28 SCE/cell).
No relevant in vivo studies with the racemic mixture of ketamine were
performed.
In 1996, study reports of a mutagenicity testing programme with the S(+)
enantiomer of ketamine were submitted to the German Federal Institute for
Drugs and Medical Devices as part of an application for a marketing autho-
risation. Since the submission was processed as a new drug application and
the applicant can still claim a period of exclusivity for the marketing autho-
risation, we are not authorised to provide any details of these studies.
However, the following general assessment may be given. The mutagenic
and clastogenic potential of the S(+) enantiomer of ketamine was tested both
in vitro and in vivo in a battery of established and validated genotoxicity
studies. The tests were conducted in compliance with GLP regulations and
were in full compliance with recent EU and ICH guidelines regarding the
scope of mutagenicity tests for new chemical entities. This means that the
following test categories, at least, were considered:
 a test for gene mutation in bacteria;
 an in vitro test with cytogenetic evaluation of chromosomal damage with
mammalian cells or an in vitro mouse lymphoma tk assay; and
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 an in vivo test for chromosomal damage using rodent hematopoietic cells.
There was no evidence of genotoxicity seen in these studies and it is there-
fore concluded that the S(+) enantiomer of ketamine is devoid of genotoxic
properties.
In conclusion, available published data from genotoxicity testing of racemic
ketamine are insufficient and do not allow a reasonable assessment of the
genotoxic potential of ketamine. Whereas negative findings were obtained
in poorly conducted (compared to current standards) bacterial tests, a posi-
tive result was reported from an SCE test in vitro. However, the effects
observed in the SCE study were only weak (i.e. less than a doubling of control
values) and thus the relevance of this finding is questionable. Moreover,
(unpublished) data from genotoxicity testing with the S(+) enantiomer of
ketamine in a standard battery of validated in vitro and in vivo tests did not
reveal any evidence of a genotoxic potential. Provided that the genotoxicity
findings with the S(+) enantiomer of ketamine can be extrapolated to the
racemate, it can be concluded that ketamine is highly unlikely to possess any
relevant genotoxic properties.
No data on the carcinogenic potential of ketamine are available.
Behavioural studies in animals
SELF-ADMINISTRATION
Animal models of addiction are used to test the induction of drug-taking
behaviour which might be similar to the recreational use of ketamine. To
date there are no animal models that incorporate all the elements of addiction.
The observation that animals readily self-administer drugs has led to the
argument of face-validity, and psychologically this is based on the reinforcing
properties of a compound. This animal model also has a high predictive
validity, although there are some limitations (Willner, 1997; Koob et al.,
1998).
Early assessments of the reinforcing properties of ketamine reported that rhesus
monkeys that had been shown to self-administer intravenously metham-
phetamine or cocaine also self-administered ketamine (0.0032–1.6 mg/kg/inj)
under limited access conditions at an intense schedule of reinforcement
(fixed ratio 1; i.e. a reward is provided after pressing the lever a fixed number
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of times). An inverted U-shaped dose-response curve was observed. A vari-
ation of the fixed ratio to about FR128 (implying that the animals have to
make more effort to obtain their reward) produced an increase in the
response rate with a factor 3 (Moreton et al., 1977). Increasing the fixed ratio
in PCP administration, however, eliminated responding (Marquis and
Moreton, 1987), suggesting a higher intrinsic power of reinforcement for
ketamine, which might be more related to the depressant action of the drugs
than to the psychotomimetic action. In baboons, however, self-administra-
tion was obtained at an FR160 schedule (Lukas et al., 1984) for both ketamine
and PCP, suggesting that the observed difference between ketamine and PCP
might be specific to rhesus monkeys. No obvious behavioural changes
occurred during exposure to doses of 0.010–0.032 mg/kg. A dose of PCP
10 times higher was associated with sedation and ataxia. Food intake was
unaffected by the lower doses.
From data on various species, it appears that drug intake tends to increase
slightly with increases in the unit dose in each species. However, the
increase does not generally occur with the self-administration of CNS
depressants such as pentobarbital and morphine (Marquis and Moreton,
1987).
DRUG DISCRIMINATION
The drug-discrimination paradigm has been developed as a way of enabling
animals to give an indication as to how a drug makes them ‘feel’. This
behavioural method offers the animal a choice, which is reinforced by pel-
leted food if they choose correctly, depending on the treatment (drug, saline
or other drug). This drug-discrimination approach is a powerful means of
differentiating between the subjective feelings (referred to as the stimulus)
evoked by various drugs (e.g. between opiates and psychomotor stimulants).
It is well established that such drug-response data can be handled as phar-
macological data showing selectivity and sensitivity.
It is generally recognised that drug-discrimination paradigms can also be
used for non-addictive drugs. However, when carefully designed, such studies
will almost certainly be of value in the assessment of common subjective
states produced by drugs (Schuster and Johanson, 1988).
Drug-discrimination data from a series of stereoisomers of compounds gen-
eralising to PCP or ketamine indicate that compounds exhibiting reinforcing
properties comparable to PCP share similar stimulus properties with this
pharmacological class (Shannon, 1981; Young et al., 1981).
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TOLERANCE, DEPENDENCE AND WITHDRAWAL
A number of studies have demonstrated tolerance to the effects of ketamine
(White and Ryan, 1996). This type of acute tolerance is related to changes at
the site of action rather than any increase in the rate of metabolism, as it can
be shown to be induced after one injection, without changing the plasma
concentration.
Continuous intravenous infusion of PCP and ketamine at maximum tolerated
dosages in rats was used to demonstrate whether dependence could be
induced by these compounds. The animals were trained to lever press for
their daily food rations under an FR30 schedule of reinforcement.
Withdrawal of PCP as well as ketamine markedly reduced response rates,
providing evidence of dependence. When the compounds were readminis-
tered, the rates increased rapidly to control rates, providing evidence of
reversal of withdrawal. Cross-dependence from ketamine to PCP was
described.
Observable withdrawal signs have been reported for rhesus monkeys with
unlimited access to ketamine self-administration. Rats chronically exposed
to ketamine exhibited subcortical withdrawal seizures without gross behav-
ioural manifestations for up to five days after self-administration was discon-
tinued (White and Ryan, 1996).
Clinical safety
Clinical experience
Ketamine is considered to be an anaesthetic with a good safety profile (Reich
and Silvay, 1989). Its major drawback, limiting its clinical use, is the occurrence
of emergence reactions. Emergence phenomena in patients awakening from
a ketamine narcosis have been described following early clinical experi-
ence, and these include hallucinations, vivid dreams, floating sensations and
delirium. These symptoms were found to be reduced by concurrent use of
benzodiazepines (notably midazolam), putting the patient in a low stimulus
environment, and by providing information preoperatively on the possibility
of emergence reactions. These emergence phenomena appear to occur more
frequently in adults (30–50 %) than in children (5–15 %) (White and Ryan,
1996; Bergman, 1999). Engelhardt (1997), reviewing eight randomised studies
in volunteers and patients, addressed the impact of S-(+)-ketamine on recovery
from anaesthesia compared with racemic ketamine. With only one exception,
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the recovery phase was clearly shorter after administration of S-(+)-ketamine
compared to racemic ketamine. However, the incidence of psychic emer-
gence reactions was lower after S-(+)-ketamine in only a single study.
Both severe respiratory depression and cardiodepressant effects have been
reported, but these adverse effects are rare with ketamine and can be managed
within the clinical setting.
Studies on street users
REPORTED FATALITIES
Table 1 presents an overview of reported deaths involving recreational use
of ketamine.
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Case Country Sex Age Reference Drugs involved
Number
Reported
1 Italy M 18 Licata et al., 1994 Ketamine
Norketamine
2 United F 31 Peyton et al., 1988 Ketamine
States
Norketamine
3 United M 46 Peyton et al., 1988 Ketamine
States
Norketamine
4 Italy M 34 Centini et al., 1987 Ketamine
Norketamine
5 United M 45 Cording et al., 1999 Ketamine
States Tiletamine
Zolazepam
6 United M 32 Moore et al., 1997 Ketamine
States
Ethanol
Nalbuphine
Table 1: Reported fatalities associated with ketamine
NB: Metabolites are in italics.
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Drugs involved Comments
Blood Urine Other
(µg/ml) (µg/ml) (µg/g)
27.4 8.51 Bile 15.2 Multiple intramuscular
Brain 3.24 doses, with a probable 
Liver 6.6 total of 1 g
Kidney 3.38
Present,
not quantified
7 Liver 6.3 Accidental intravenous 
Kidney 3.2 overdose (probably 900 mg)
Lung 1.6
Heart 2.4
Present,
not quantified
3 Liver 0.8 Gunshot victim who was 
Kidney 0.6 given ketamine during 
Spleen 0.8 surgery (case included for 
Brain 4.0 comparison with Case 2)
Lung 2.2
Heart 3.5
Not present
Liver 12.2
Brain 3.7
Lung 16.4
Kidney 15.5
Spleen 14.1
Liver 0.15
Lung 0.17
Kidney 0.7
Spleen 0.12
0.037 0.381 Mixed-drug intoxication
0.295 0.682 Liver 0.196
1.71 1.33 Liver 15.5
1.8 2 Brain 4.3 Mixed-drug fatality due to 
Spleen 6.1 ethanol and ketamine
Liver 4.9
Kidney 3.6
170
< 0.020 
Case
Number
1
2
3
4
5
6
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Case Country Sex Age Reference Drugs involved
Number
Reported
7 France F Gaillard and Pepin, 1998 Ketamine
Norketamine
Chloroform
Cocaine
Benzoylecgonine
Methylecgonine
ester
Anhydroecgonine
ester
Codeine
6-acetylmorphine
Morphine
Thiopental
Pentobarbital
Diazepam
Nordiazepam
Oxazepam
8 France M 19 Arditti, 2000 Ketamine
LSD
Ecstasy
9 Ireland Europol/EMCDDA, 2000 Ketamine
Opioids
10 Ireland Europol/EMCDDA, 2000 Ketamine
Ephedrine
Pseudoephedrine
11, 12, 13 United NIDA, 2000
States
The circumstances of the death of Case 1 indicated that the victim probably
received around 1 g of ketamine intramuscularly, divided over several doses.
A long period of time may have elapsed between the first dose and the
victim’s death. The last dose was probably administered shortly before death.
Case 2 is another case of ketamine overdose, without the involvement of
other drugs. Case 3, a gunshot victim who was administered ketamine for
anaesthesia during surgery but died as a result of his injuries, was included
only for comparison of ketamine tissue values with Case 2. Blood ketamine
concentrations in Case 2 were only two to three times higher than those in
NB: Metabolites are in italics.
57
Drugs involved Comments
Blood Urine Other
(µg/ml) (µg/ml) (µg/g)
1.4 Present Hair 11.3 Polydrug addict
Present Hair 1.0
30.7 Present
0.576 Present Hair 5.5
Present Hair 1.5
0.78 Present Hair 1.0
0.12 Present
0.013 Present
Present Hair 4.4
0.420 Present Hair 3.4
1.97 Hair 5.3
2.64 Hair 10.0
0.070 Hair 1.2
0.2 Hair 0.1
Present
Notification by l’OCRTIS. 
No details available
No details available
No details available
Three ketamine deaths 
were reported in New
Orleans in 1998.
No details available.
Case
Number
7
8
9
10
11,12,13
the gunshot victim. However, tissue concentrations showed that distribution
throughout the body had taken place in the overdose victim and that the
administered dose may have been much higher than an anaesthetic dose.
Based on these data and on circumstantial evidence, the case was ruled to be
caused by an accidental intravenous overdose of ketamine, possibly 900 mg.
Comparison of the data from Case 2 and Case 3 indicates that the presence
of the metabolite norketamine and the tissue distribution are important for
establishing whether a short or a long period of time elapsed between the
administration of the drug and death.
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The presence of a number of empty Ketalar bottles and numerous punctures
in the elbow fold indicated that the deceased in Case 4, found dead with a
syringe in his arm, was a repeated intravenous user of ketamine. Tissue levels
indicated that the victim died due to an overdose. Blood, urine and bile con-
centrations were not obtainable due to the advanced state of decomposition
of the victim. Pathology showed diffused lung oedema.
In Case 5, ketamine concentrations were low and may not have contributed
to the cause of death. In this case, apart from ketamine, a pharmaceutical
preparation for veterinary use was administered in which tiletamine, which
is another dissociative anaesthetic, is combined with zolazepam, a benzo-
diazepine.
In Case 6, the victim had been drinking with friends during the evening. 
He died early in the morning. Ethanol, a CNS and respiratory depressant,
may have added to the respiratory depressant effect of ketamine and thus
have contributed to this (mixed-drug) fatality.
Case 7 concerns a polydrug addict who was abusing heroin, codeine, ketamine,
cocaine, benzodiazepine and barbiturates. The ketamine blood concentration
was in the anaesthetic range and this may have contributed to the cause of
death. However, the multitude of drugs used by this victim makes it impos-
sible to determine which drugs were major contributors. Both the respiratory
depressant effects of other substances, notably opioids, barbiturate and ben-
zodiazepine, and the cardiostimulant effects of cocaine may have exacer-
bated the potentially deleterious side-effects of ketamine.
Case 8 was mentioned by Arditti (2000) and Cases 9 and 10 were referred to
in the Europol and EMCDDA joint progress report. However, no details were
provided, so the importance of the role of ketamine in these three deaths
cannot be evaluated. Finally, an Internet site for NIDA mentions three fatal
ketamine cases (Cases 11, 12 and 13 in Table 1), but, again, no details were
provided.
The following conclusions can be drawn from this survey.
 Only three reported fatal ketamine intoxications involving ketamine were
identified. In these cases the intramuscular or intravenous route was used.
Two reports concern mixed-drug fatalities. In one case, ketamine played
only a minor role. For the remaining six cases, insufficient details were
available for a proper evaluation.
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 From the cases listed in Table 1, it can be learned that the ketamine blood
concentrations were usually in the anaesthetic range or above. Tissue dis-
tribution data and norketamine concentrations give insight into the total
amount administered and the period of time that elapsed between the first
dose and death. Where clues (usually empty ketamine vials) about the
quantity administered were available, such indicators suggested amounts
of approximately 1 g administered intravenously or intramuscularly in the
absence of other substances. Based on a body weight of 60 kg, such a dose
is 4–17 times the recommended intravenous dose for anaesthesia or
1.3–2.5 times the recommended intramuscular dose for anaesthesia. The
intravenous data are in line with preclinical findings. In squirrel monkeys,
death occurred when ketamine was administered intravenously at a
dosage more than 10 times the dose that produces anaesthesia
(Greenstein, 1975). The relatively small margin of safety for the acute tox-
icity that applies to the intramuscular route is unexplained. Based on clin-
ical experience and pharmacokinetic considerations, the acute toxicity is
lower using the intramuscular route than the intravenous route. It is possi-
ble that the greater prevalence of this route of administration led to the
emergence of fatalities in individuals with increased susceptibility due to
premorbid conditions or deviant pharmacokinetics.
 The reported ketamine concentrations found in multiple drug users are lower
than those found in the few cases involving ketamine only. This indicates
that drug interactions may have contributed to these deaths. In this respect,
substances with CNS/respiratory depressant effects, like ethanol, opioids,
barbiturates and benzodiazepine, or substances with cardiostimulant
effects, like cocaine and amphetamine, are indicated as drugs that may
increase ketamine toxicity.
NON-FATAL INTOXICATION
The pharmacological action of ketamine may produce side-effects, many of
which have been reported by recreational users (Siegel, 1978; Dalgarno and
Shewan, 1996; Weiner et al., 2000). Ataxia, disorientation and anxiety are
the most frequent complaints, especially in first-time users. Other side-effects
were slurred speech, dizziness, blurred vision, palpitations, chest pain, vom-
iting and insomnia. The most frequent finding in users that were given a
physical examination at an emergency department was tachycardia (Weiner
et al., 2000). Nystagmus was, unlike with PCP, rather infrequent in this group
of ketamine users. Complications such as hyperthermia, seizure or dysrythmia
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were not encountered in Weiner’s study group, but two cases of rhabdo-
myolysis were noted (Weiner et al., 2000).
In an overview presented by a French report on ketamine (Arditti, 2000), 19 cases
of non-fatal intoxication were mentioned that were registered by the CEIP
between 1991 and 2000. The majority were recorded during the last four
years. The most frequently observed adverse effects were neurobehavioural:
agitation, delirium, consciousness disturbances (e.g. loss of sense of danger,
sensation of floating, attempts to jump out of a window, amnesia, obsession)
and motor function impairment. Less frequently mentioned adverse effects
were anxiety, neuropathy of the Guillain-Barré type and physical effects such
as general stiffness, raised body temperature (38°C), rhabdomyolysis, hepatic
crisis, myalgia and mydriasis.
Felser and Orban (1982) have described a case of dystonic reaction after
self-administration of ketamine.
A case of hypertension and pulmonary oedema was triggered by ketamine
anaesthesia in an obstetric patient with a history of abusing multiple drugs
(Murphy, 1993). The role of ketamine in this case is not as a drug of abuse
but as an anaesthetic. This case shows that potentially dangerous interac-
tions may exist when different drugs of abuse are combined. The hyperten-
sion was largely attributed to barbiturate withdrawal, and the use of cocaine
may have predisposed the patient to developing increased pulmonary capillary
hydrostatic pressure, thus causing pulmonary oedema. However, ketamine,
being a sympathomimetic agent, may have triggered the hypertension and
pulmonary oedema.
The following conclusions can be drawn.
 The main effects of non-fatal ketamine intoxication are neurobehavioural:
anxiety (especially in first-time users), agitation, changes of perception
(e.g. loss of sense of danger, visual disturbances) and impairment of motor
function. In such a condition the user will have severely impaired self-con-
trol, which poses a risk of injury of him- or herself or others (e.g. when dri-
ving in traffic).
 Common side-effects reported by users were slurred speech, dizziness,
blurred vision, palpitations, chest pain, vomiting and insomnia. The pre-
dominant symptom found on physical examination of users that went to
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an emergency department was tachycardia. Rhabdomyolysis was noted in
several cases. Other physical side-effects appear to be rare.
 Serious side-effects like hypertension and lung oedema have been reported.
Such adverse effects appear to be rare and may be related to the combi-
nation of ketamine with other drugs of abuse.
EMERGENCY TREATMENT
In this section, the treatment of patients presenting to an emergency depart-
ment is considered.
The following advice is taken from Weiner et al. (2000):
‘Based on our experience, we offer the following treatment recom-
mendations for evaluating Emergency Department patients who pre-
sent after having abused ketamine. This diagnosis should be suspected
in patients (especially young patients) who present with agitation,
tachycardia, and either visual hallucinations or nystagmus. However,
the absence of the latter two findings does not rule out the possibility
of ketamine abuse. When laboratory confirmation of the diagnosis of
ketamine abuse is critical to the patient’s management (which is hardly
ever the case), one of the aforementioned tests can be used (GC/MS
or HPLC).’
‘Symptomatic patients are best managed with standard supportive
care, as the effects of the drug are usually short-lived. Keeping the
patient in a quiet environment, with a minimum of external stimuli,
may prevent excessive agitation. Benzodiazepines should be used for
sedation in agitated patients who are at risk for self-injury, hyperthermia,
and rhabdomyolysis. Intravenous fluids should be given to agitated
patients at a generous rate until laboratory testing has ruled out rhab-
domyolysis. Activated charcoal is not necessary after ketamine abuse
unless there is evidence that an oral coingestant may be contributing
to the patient’s symptoms. All patients must be observed until their
vital signs and mental status have normalised. Symptoms not improving
within 2 h of presentation should prompt a search for other drugs of
abuse or another disease process. The differential diagnosis of drug- or
toxin-induced hallucinations should include LSD, hallucinogenic
mushrooms, amphetamine, PCP, ketamine, cocaine, anticholinergic
drugs, and a variety of plants, especially morning glory, jimson weed,
and nutmeg.’
62
The advice given above is comprehensive, although the list of drugs men-
tioned at the end for differential diagnosis may vary in time and from region
to region. Amphetamine analogues (e.g. MDMA, DOB) should be included.
Additionally, special attention should be paid to observation of respiratory
and cardiovascular functions. Respiratory depression and cardiovascular
pathology are ketamine-induced side-effects that are rarely serious when
ketamine is used solely, but which may be more serious when other drugs
are used as well. The phenomenon of multiple drug-taking is very prevalent
in patients presenting to emergency departments (Spaans et al., 1999).
DRUG INTERACTIONS
There are no known studies specifically addressing the problems of recre-
ational use of ketamine and concomitant abuse of other drugs. However,
preclinical data, data from fatal intoxication discussed above, clinical experience
with ketamine as an anaesthetic and general pharmacodynamic and phar-
macokinetic considerations do give some clues about possible interactions
between ketamine and other recreational substances. These will be discussed
below according to type of interaction.
CNS and/or respiratory depression: An early case report mentions severe
respiratory depression in a seven-year-old patient given a subanaesthetic
dose of ketamine (approximately 3.3 mg/kg i.m.) after premedication with
secobarbital (Kopman, 1972).
Opioids have a known respiratory depressant effect (Buck and Blumer, 1991)
and may therefore have an additive effect on the respiratory depression
induced by ketamine.
Ethanol, another respiratory depressant, has been implicated in a mixed-drug
fatality involving ethanol and ketamine (Moore et al., 1997).
Benzodiazepine is known to potentiate respiratory depressant agents.
Flunitrazepam (Rohypnol) is known to induce respiratory depression in
patients with chronic airway obstruction. Fatal cases associated solely with
flunitrazepam have been described. Therefore, it may be anticipated that the
combined use of flunitrazepam and ketamine may also increase the risk of
severe respiratory depression.
These examples show that respiratory depressants like ethanol, opioids, bar-
biturates and benzodiazepine (flunitrazepam) may add to the respiratory
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depression induced by ketamine and thus may provoke a dangerous inter-
action between these substances. Furthermore, these substances are CNS
depressants as well and so may deepen or lengthen the ketamine-induced
anaesthetic state.
Sympathomimetic effects: Ketamine has sympathomimetic properties. Inhibition
of central catecholamine re-uptake and increased levels of circulating cate-
cholamines are believed to cause the cardiovascular stimulant effects. This
implies that ketamine may add to the sympathomimetic effects of others
drugs such as amphetamine and its analogues, ephedrine and cocaine.
Hypertension, tachycardia and lung oedema have been reported in a patient
receiving ketamine who appeared also to be abusing cocaine (amongst other
substances) (Murphy, 1993). However, barbiturate withdrawal may have
played a major role in this case (see the section, ‘Non-fatal intoxication’,
page 59).
On the other hand, cardiodepressant effects have been noted in critically ill
patients. This may be due to chronic catecholamine depletion inhibiting the
sympathomimetic effects of ketamine and unmasking a negative inotropic
effect which is usually overshadowed by sympathetic stimulation (Reich and
Silvay, 1989; White and Ryan, 1996). It may be hypothesised that drug users
bingeing on stimulatory drugs may provoke a degree of catecholamine
depletion. Therefore, the possibility of ketamine producing a cardiodepressant
effect cannot be excluded under such extreme conditions.
Mixed CNS effects: Benzodiazepines clinically are used to reduce the occur-
rence of emergence phenomena (hallucinations, vivid dreams, etc.) associ-
ated with ketamine anaesthesia (Haas and Harper, 1992). Krystal et al.
(1998) studied the interactive effects of subhypnotic doses of lorazepam and
subanaesthetic doses of ketamine. Lorazepam reduced ketamine-associated
emotional distress and there was also a non-significant tendency for it to
decrease any perceptual alterations induced by ketamine. However, it failed
to reduce many of the cognitive and behavioural effects of ketamine, including
psychosis. Furthermore, lorazepam exacerbated the sedative, attention-
impairing, and amnesiac effects of ketamine.
Potential neurotoxicity: Olney and co-workers (1989, 1991) described how
neurotoxicity was induced in rats by the administration of ketamine (see the
section ‘Neurotoxicity’, page 44). If the postulated mechanism for such a
ketamine-induced neurotoxicity is applicable to the human recreational use
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of ketamine, it may be anticipated that several substances from the recre-
ational drug repertoire might enhance such neurotoxicity: Amanita muscaria
mushrooms (muscarinic agonist), alcohol (NMDA- and (partial) GABAA-
antagonist), yohimbine (α2-adrenergic receptor antagonist), and other disso-
ciative drugs (NMDA-antagonists) like PCP and tiletamine.
Pharmacokinetic interactions: Ketamine and its primary metabolite, norket-
amine, are metabolised by enzymes from the cytochrome P450 (CYP) family.
However, in the absence of more detailed information on which CYPs are
involved and whether ketamine may induce or inhibit specific CYPs, it is not
yet possible to evaluate interactions at this level. This point demands further
attention in the future, especially since the possibility of involvement of
CYP3A4, an isozyme that is susceptible to this kind of interaction and that is
involved in the metabolism of medicines (e.g. protease inhibitors used in
HIV therapy), cannot be excluded.
Psychological risk assessment (cognition, 
mood and mental functioning)
Acute effects
Studies investigating the pathophysiology of schizophrenia, using ketamine
as a model substance, and studies investigating the psychotropic effects of
ketamine in their own right have provided a good characterisation of the
psychotomimetic action of ketamine (e.g. Krystal et al., 1994; Hartvig et al.,
1995; Malhotra et al., 1996; Vollenweider et al., 1997, 2000; Bowdle et al.,
1998; Adler et al., 1999; Oranje et al., 2000). It appears that ketamine in
subanaesthetic doses induces a state of mind that both neurophysiologically
and behaviourally resembles that of schizophrenic psychosis. This may be
experienced by the experimental or recreational drug user as an altered,
‘psychedelic’, state of mind that allows him to travel beyond the boundaries
of ordinary existence.
Effects on cognitive functioning (neuropsychological assessment)
Ketamine acutely affects cognitive performance, including attention, working
memory and semantic memory.
In a double-blind randomised crossover study with five healthy volunteers,
Hartvig et al. (1995) showed, by means of a word recall test, that short-term
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memory could be impaired dose-dependently by intravenous administration
of 0.1 and 0.2 mg/kg. Ketamine binding in the brain correlated well with the
regional distribution of NMDA-receptors.
Ketamine hydrochloride (0.1 or 0.5 mg/kg i.v. during 40 minutes) did not
have a significant effect on the mini-mental state examination (a brief bedside
evaluation of cognition) in healthy subjects (n = 18). However, tests of
vigilance, verbal fluency and the Wisconsin Card sorting test showed a dose-
dependent impairment (Krystal et al., 1994). Delayed word recall was
reduced, but immediate and post-distraction recall were spared.
Malhotra et al. (1996) assessed the effects of ketamine (total dose 0.77 mg/kg
i.v. during 1 hour) on attention, free recall of category-related words and
recognition memory of category-related words. All three cognitive functions
showed significant decrements. Memory impairments were not accounted for
by the changes in the subjects’ attention and did not correlate to psychosis
ratings. In further studies, Adler et al. (1998) found that ketamine-induced
thought disorder significantly correlated with decrements in working memory
but did not correlate with ketamine-induced impairments in semantic memory.
Effects on emotional status, behavioural patterns and personality
(psychological instruments, rating scales)
Ketamine profoundly affects perception of body, time, surroundings and
reality. A study on 10 psychiatrically healthy volunteers was performed by
Bowdle et al. (1998). The subjects were intravenously administered an esca-
lating dose of ketamine by infusion with plasma target concentration of
0.050, 0.100, 0.150 and 0.200 µg/ml. Each step was maintained for 20 minutes
and the subjects were asked to rate various aspects of their consciousness on
a visual analogue scale (VAS). A good correlation between the plasma keta-
mine concentrations and the VAS ratings was obtained. The following VAS
scores were increased by ketamine, compared with a saline control.
Body: Body or body parts seemed to change their position or shape.
Surroundings: Surroundings seemed to change size, depth or shape.
Time: The passing of time was altered.
Reality: There were feelings of unreality.
Thoughts: There was difficulty controlling thoughts.
Colours: The intensity of colours changed.
Sound: The intensity of sound changed.
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Voices: Unreal voices or sounds were heard.
Meaning: Subjects believed that events, objects or other people had partic-
ular meaning that was specific to them.
High: They felt high.
Drowsy: They felt drowsy.
Anxious: They felt anxious.
The intensity of the effects was greatest for High, Reality, Time,
Surroundings, Thought and Sound. They were lowest for Anxiety and
Meaning. There was not a significant difference for Suspicious (subject felt
suspicious).
This study clearly shows that there is a dose–effect relationship between
ketamine dose and intensity of ‘psychedelic’ effects. The quality and type of
effects were exemplified in the following ways: ‘tingling sensation in the
limbs, followed by numbness’; ‘floating, very carefree feelings throughout
entire body’; ‘felt so different. Wasn’t able to describe the way I was feeling’;
‘floating in space’; ‘almost complete annihilation of physical self, shrunken’;
‘dizzy, shaky, light-headed’. One subject wrote the following: ‘The experience
seems to be a mystical experience, an incomprehensible comprehension of
the universe. There seemed to be no past, present or future, no time, just
existence. Life and death at the same time.’ All but one participant sponta-
neously reported feelings of intoxication and perceptual distortion during 
the ketamine infusion; one of these persons also reported these symptoms
during the placebo infusion. Three participants became moderately dysphoric
during the ketamine infusion, but none of them experienced dysphoria during
the placebo infusion. One participant developed a mildly paranoid state
characterised by multiple questions about the procedure and an intense
affect. Another volunteer, who had experienced emotional stress in the
recent past, experienced tearfulness, a sad mood and moderately intense
ruminations about recent stressful events.
Krystal et al. (1994) also included a VAS of mood states in their study of 18
healthy volunteers after intravenous administration of 0.1 or 0.5 mg/kg
ketamine hydrochloride for 40 minutes. They observed a biphasic effect on
Anxiety, the low dose decreasing anxiety and the high dose increasing anxiety.
The VAS rating for High was increased dose-dependently.
Hartvig et al. (1995) studied the psychotomimetic effect of low intravenous
doses (0.1 and 0.2 mg/kg) of ketamine in a double-blind randomised
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crossover study in five healthy volunteers. All subjects having peak plasma
ketamine concentrations of 0.07 µg/ml or above or estimated peak regional
brain ketamine concentrations of 0.5 µg/ml or above experienced psy-
chotomimetic effects. These consisted of pronounced feelings of unreality,
altered perception of body image, sensations of impaired recognition of the
limbs, detachment from the body, and modulation in hearing, characterised
by preoccupation with unimportant sounds. The intensity of the effects
showed a dose–response relation with the degree of regional brain binding
of ketamine.
Vollenweider and co-workers (1997) investigated the differential effects of 
S- and R-ketamine and found that S-ketamine is responsible for the psy-
chotomimetic effects, whereas R-ketamine induced a state of relaxation.
Results of a mood rating scale for S-ketamine showed increased scores for
‘deactivation’, ‘introversion’, negative and dysphoric feelings and anxiety.
All subjects reported distortion of body image, loosening of ego-boundaries
and alterations of sense of time and space, variously associated with emo-
tional changes such as euphoria (30 %), indifference (30 %) or heightened
anxiety (40 %).
In an open uncontrolled study (Hansen et al., 1988), seven individuals working
in health care (two psychiatrists, one psychiatrist in training, one anaesthesi-
ologist, one body therapist, one general practitioner and one medical student)
explored the psychotropic effects of ketamine for its use as a possible adjunct
in psychotherapy by intravenous, intramuscular and oral self-administration
of various subanaesthetic doses. They recorded that their inner experiences
were extremely intense and possessed of a subjective quality which made it
difficult to put them into writing. To a certain extent, their experiences varied
from subject to subject and, even for the same subject, from one session to
another. Nevertheless, all the subjects experienced most of the following
phenomena:
 a sensation of light throughout the body;
 novel experiences concerning ‘body consistency’ (e.g. being described as
made up of dry wood, foam rubber or plastic);
 grotesquely distorted shape or unreal size of body parts (e.g. extremely
large or small);
 a sensation of floating or hovering in a weightless condition in space;
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 radiantly colourful visions (e.g. a sense of moving between rooms that are
filled with moving, glowing geometrical patterns and figures);
 complete absence of a sense of time (i.e. an experience of virtual time-
lessness or eternity);
 periodic, sudden insight into the riddles of existence or of the self; occa-
sionally, an experience of compelling emotional consanguinity, at times
extending to sensations of melting together with someone or something in
the environment; and
 an experience of leaving the body (i.e. an out-of-body experience).
In nearly every instance, subjects retained the sense of a sober, witnessing ‘I’
that could both observe and consider as well as be amazed, overjoyed or
perhaps anxious, and that could, to a certain extent, later remember the
unusual phenomena. Music played an important role in their experiences
(synaesthesia), as exemplified by the following remarks:
‘... the music has substance, the music itself made up the very walls
in these endless rooms, it directed both upward and downward flight.’
‘... the music was very nearly material; it could be touched and felt,
as if it had been a sculpture.’
Other examples show that people under the influence of ketamine may have
experiences related to death or expanding consciousness:
‘... I am completely and irrevocably removed from my body and have
this experience: this is death, you will never return. All such reflection
ends, and I am floating out in space. I am in a timeless world filled
with a profusion of light, colour, warmth and joy.’
‘... it was clear that what I was experiencing was from beyond death
— I bounded from insight to insight.’
‘... it felt as if I rolled backward and upward out of my body. My con-
sciousness rose up in an amazing way, crested upward and spread out
into another dimension, which was ‘I’-less. I was there for only a short
time and went back to the normal dimension in the same way I had
69
come. The area in which I had been was hazy and lacked structure,
but I noticed that I could return again and learn to understand it and
to spread light into it.’
Effects on psychopathological status — psychiatric comorbidity
Studies in healthy volunteers given ketamine and schizophrenic patients
have shown that ketamine produces a clinical syndrome with aspects that
resemble key symptoms of schizophrenia.
Krystal et al. (1994) assessed four key positive and three key negative symp-
toms of schizophrenia in healthy subjects after intravenous administration of
0.1 or 0.5 mg/kg ketamine hydrochloride for 40 minutes. The positive symp-
toms were conceptual disorganisation, hallucinatory behaviour, suspiciousness
and unusual thought content. The negative symptoms were blunted affect,
emotional withdrawal and motor retardation. Ketamine produced a dose-
dependent increase in scores for both positive and negative symptoms.
Similarly, scores for key symptoms of schizophrenia (conceptual disorgani-
sation and disorganised speech, unusual thought content, emotional with-
drawal, psychomotor retardation and blunted affect) were increased by
ketamine (Malhotra et al., 1996).
Adler and co-workers (1998, 1999) studied the effects of ketamine on
thought disorder and compared these effects with thought disorder in
patients with schizophrenia. They found similar scores for 19 of 20 items on
the ‘Scale for the assessment of thought, language and communication’.
Only the score for ‘perseveration’ was lower in schizophrenic patients.
However, after Bonferoni correction, this difference was no longer statisti-
cally significant. A total dose of 0.56 mg/kg of ketamine over 125 minutes
was infused in healthy volunteers (n = 19) to obtain a pseudo steady state
plasma ketamine concentration of 0.134 µg/ml. Reduced processing nega-
tivity and P300 amplitude, psychophysiological anomalies commonly
observed in schizophrenic patients, were recorded. However, no drug effect
on mismatch negativity, another parameter that is commonly reduced in
schizophrenic subjects, was found (Oranje et al., 2000).
Vollenweider and co-workers (2000) observed a negative correlation
between raclopride binding potency in the ventral striatum and S-ketamine-
induced euphoria and mania-like symptoms, suggesting a role for elevated
striatal dopamine levels in these positive symptoms.
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Chronic effects
Effects on cognition, mood and mental functioning
Short-term exposure to ketamine appears not to induce any long-term
adverse effects on cognition, mood or personality. Long-term heavy use of
ketamine may be associated with persistant deficits in attention and recall.
However, such a condition has been documented only once in the literature.
CLINICAL STUDIES IN VOLUNTEERS
In a follow-up interview in a study by Krystal et al. (1994) of healthy volun-
teers given ketamine hydrochloride (0.1 or 0.5 mg/kg), no subject had
lingering or recurrent physiological or psychological effects, such as night-
mares, flashbacks or perceptual alterations, following a test day.
The subjects in the study conducted by Hansen et al. (1988) did not report
long-term side-effects of any kind for up to three years following the
ketamine sessions.
Corssen et al. (1971) studied 30 volunteers from a prison population who
were given either ketamine or thiopentone or served as a control.
Psychological assessment was performed before and at one week, four
weeks and six months after drug administration. The study could not identi-
fy a difference between the three groups.
STUDIES IN PATIENTS
Psychological changes were compared in 221 patients following ketamine
anaesthesia and patients receiving other anaesthetics. Psychometric tests
were applied repeatedly for more than one year (Albin et al., 1970). There
were no significant differences between groups in terms of mental perfor-
mance, hallucinations and behavioural factors.
Seven case reports of prolonged (from several weeks up to one year) psychic
phenomena after a single (or, in one case, dual) exposure were reviewed by
Steen and Michenfelder (1979). In one patient, serious effects persisted for
five days and in three others there were only minor disturbances for three
weeks. Severe congenital brain abnormalities were present in two patients.
One patient complained of hallucinations, ‘passing out spells’ and feelings
of unreality and hesitation. These symptoms could have been linked to a
single-dose exposure to ketamine one year earlier, but this seems unlikely.
71
STUDIES IN RECREATIONAL USERS
Siegel (1978) stated that subjects who reported long-term use of ketamine
sometimes complained of ‘flashbacks’, attention dysfunction and decreased
sociability. Positive effects on mood were mentioned as well, which rein-
forced the drug use. However, standard psychometric tests did not reveal
personality changes. The subjects described were mostly polydrug users,
those snorting ketamine also using cocaine. Unlike the PCP group described
in the same paper, a tendency to transient psychosis was not noted.
Amongst 20 recreational drug users studied by Dalgarno and Shewan
(1996), lasting psychological effects were not reported. Eleven of them used
ketamine less than 10 times, eight used it between 10 and 20 times and only
one reported use on approximately 100 occasions. The last subject, who was
an experienced polydrug user, reported ‘a total loss of reality’ during a
month-long ketamine binge, after which he stopped using it completely
without major difficulties. He reported subsequently having very lucid
dreams similar in nature to the ketamine-induced state. These dreams less-
ened in intensity and ceased completely within 7 to 10 days of the final ket-
amine episode.
Jansen (1990) describes one case in which a subject had persistent impaired
recall and attention and a subtle visual anomaly after cessation of long-term,
high-dose ketamine use.
Psychological effects of drug-using careers
Dependence potential in humans
TOLERANCE
Tolerance to ketamine develops rapidly and can be high. The subject of one
case report related the history of his ketamine use. During the first two years,
his consumption developed from an occasional oral dose of 50 mg to 500 mg
four to five times a day. Switching to intramuscular injection, he was injecting
300–750 mg five to six times a day within a month. The tolerance dissipated
on stopping the habit, but redeveloped at the same rate (within a month)
after restarting intramuscular injections (Kamaya and Krishna, 1987).
ABSTINENCE SYMPTOMS
There is no evidence that ketamine causes an abstinence syndrome in
humans. The subject described in the case report by Kamaya and Krishna
72
(1987) found stopping the habit extremely difficult but never experienced a
withdrawal syndrome.
Of 20 recreational ketamine users described by Dalgarno and Shewan
(1996), 11 never experienced mental after-effects and eight never experi-
enced physical after-effects following a ketamine episode. Of those that did
experience mental after-effects, three reported a general feeling of well-
being, two had a desire for physical contact, two felt mildly depressed and
‘flat’ and two said they felt ‘dopey’ (like being under the influence of
cannabis). Of those that experienced physical after-effects, three reported a
general feeling of contentment and happiness, four said they felt mildly
‘hung over’ or drained, three experienced vomiting, one said he felt physi-
cally and positively changed and one felt nauseous.
Jansen (2000b) states that an elevated mood after a ketamine binge is a com-
mon experience, whereas a cocaine-like swing into depression is rare. 
He suggests that high levels of norketamine can take days to subside, thereby
providing a ‘deflating cushion’. However, no evidence is provided for such
a theory. In rats, norketamine-induced anaesthesia and locomotor activity
are of shorter duration than when these effects are induced by ketamine.
Both ketamine and norketamine are rapidly cleared from blood and brain
(Leung and Baillie, 1986).
DRUG-SEEKING BEHAVIOUR AND ADDICTION
A distinction may be drawn between experimental (Ahmed and
Petchkowsky, 1980) and dependent ketamine use (Kamaya and Krishna,
1987; Hurt and Ritchie, 1994). In dependent users, use of the drug continues
despite increasingly apparent effects on their work or on their health. Of the
20 users described by Dalgarno and Shewan (1996), 7 had used ketamine
once or twice and only 3 had used it 15 times or more. One user in this
group reported that he had believed the experience was ‘never going to end’
and another experienced extreme dissociation. These two never repeated
their first-time use. It appears that this dissociative experience discourages
some experimental users. Another reason for limited use mentioned in this
study was the scarcity of the drug. On the other side of the spectrum, one
user in this study group said he believed he had been addicted to using
ketamine during his heaviest period of its use.
According to Jansen (2000b), tolerance to the effects of ketamine soon devel-
ops and, with higher doses, the ability to remember the experience is sharply
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reduced. Where many stop at this point, others carry on with compulsive
binges which result in cocaine-like stimulation, opiate-like calming,
cannabis-like imagery (which also disappears), alcohol-like intoxication,
and relief from anxiety, depression and mental craving (Jansen, 2000b).
Jansen states that repeated users of ketamine may rapidly become addicted.
This addictive side of ketamine (in the sense of psychological dependence)
may be more pronounced for those who persist in compulsive binges.
No reliable data on the prevalence of long-term use are available.
Three well-known ketamine histories are those of John Lilly (1978), Marcia
Moore (1978) and D.M. Turner (1994). The first was still using ketamine at
the age of 83, even though at some point in his life he had elected to be
hospitalised for ketamine withdrawal. The second, according to her husband,
Howard Altounian, became addicted and committed suicide. The third slipped
below the waterline in his bathtub, with a half-empty bottle of ketamine at
his side.
Psychological factors that increase the probability of harm
No systematic studies were found on personality traits or other psychological
factors which could lead to ketamine use or affect the probability of harm.
Jansen (2000b) describes several conditions that may motivate ketamine use.
Amongst these is a characteristic of the ketamine experience which may be
described as escape from reality. Few drugs offer such a powerful experi-
ence of entering a different reality, which is experienced as no less real than
reality without the drug. This possibility for escape and discovery may
appeal to some individuals, especially those who are discontented with their
ordinary existence and are looking for meaning in their life. In this way, the
ketamine experience offers a psychological reward, which contributes to the
development of addiction.
For those interested in taking as much and as many drugs as possible, the
sensation-seeking factor will certainly be important (Laviola et al., 1999).
Ketamine, advertised as the ultimate psychedelic journey (Turner, 1994),
will appeal to drug users looking for extreme experiences.
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Conclusions
 Ketamine has existed for 37 years and is a registered medicine in EU
Member States. It cannot be regarded as a new synthetic drug.
 Ketamine is in use in human and veterinary medicine as an anaesthetic
and analgesic agent.
 Ketamine is a dissociative anaesthetic. It binds to the PCP-site of the
NMDA-receptor, thus acting as a non-competitive NMDA-antagonist.
Ketamine enhances striatal dopaminergic activity.
 Therapeutic use of ketamine in humans is limited due to the occurrence of
emergence reactions (patients experiencing vivid dreams, hallucinations,
and disorientation when emerging from anaesthesia). Veterinary use of
ketamine is widespread in the EU and it would be difficult to replace it
with another drug.
 Administration of ketamine for recreational use is predominantly by the nasal
route, but it is also taken orally and by injection (usually intramuscular).
 Taken orally, the bioavailability of ketamine is low. However, the primary
metabolite, norketamine, still has one third of the pharmacological activity
of the parent compound.
 The main psychological effects are as follows:
— ketamine acutely affects cognitive performance, including attention,
working memory and semantic memory;
— it profoundly affects perception of body, time, surroundings and reali-
ty; and
— it produces a clinical syndrome with effects that resemble key symp-
toms of schizophrenia.
 The main risks associated with the recreational use of ketamine are as
follows.
— Ketamine has the potential to cause psychological dependence in
some individuals. Self-administration and generalisation to other com-
pounds of the PCP class in drug-discrimination tests have been
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demonstrated in animals. There is evidence of physical dependence in
animals, but this is not severe. Cases of psychological dependence in
humans have been described. The prevalence is unknown.
— The acute psychological effects of ketamine may lead to loss of self
control and subsequently increase the risk of self-injury and accidents.
— Acute ketamine intoxication presents itself clinically with tachycar-
dia, agitation, hallucinations, anxiety, changes in perception of reali-
ty, impaired motor function, rhabdomyolysis, slurred speech, dizzi-
ness, blurred vision, palpitations, chest pain, vomiting and insomnia.
Not all of these symptoms need to be present. In serious cases, hyper-
tension and lung oedema have been observed. Several cases have
been described in which death was attributed to the recreational use
of ketamine, either alone or in combination with other substances.
— Preclinical data that may be relevant for the recreational ketamine
user are findings concerning neurotoxicity and reproductive toxicity.
However, to date there are no clinical data to support these findings.
 The following conditions, which increase the risks associated with the use
of ketamine, should be regarded as contraindications:
— psychiatric disorders;
— history of substance abuse; and
— cardiovascular pathology.
 Substances that result in pharmacological interactions with ketamine and
therefore increase the risks associated with the use of ketamine are:
— CNS and respiratory depressants; notably, ethanol, opioids, barbitu-
rates and benzodiazepines (flunitrazepam);
— sympathomimetic agents; notably, cocaine, amphetamine and its
congeners, and other substances causing inhibition of central cate-
cholamine re-uptake or increasing levels of circulating cate-
cholamines.
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Sociological and criminological (Europol) 
evidence
Introduction
Non-medical use of ketamine was not noted in Europe until the 1990s. In
1995 and 1996, concern in the United Kingdom about the prevalence of
misuse and health risks associated with ketamine escalated and the Advisory
Council for the Misuse of Drugs recommended continued monitoring of the
drug. This report summarises the relevant data required by the Technical
Annex C of the Guidelines for the risk assessment of new synthetic drugs.
In the absence of systematic studies of non-medical use of ketamine, the
sociological and criminological evidence is based on information collected
from:
 the Reitox national focal points in the 15 EU Member States (1);
 Europol’s contribution to the risk assessment of ketamine (2);
 the EMEA contribution to the risk assessment of ketamine (3);
 the Qualitative European Drugs Network (QED) (4);
 the literature (5);
 key European forensic scientists (6);
 key toxicologists in the United Kingdom (7);
 telephone interviews with international experts in the field of recreational
drugs (8);
 the Internet (English-language searches) (9); and
 youth and mass media (English-language searches) (10).
Table 2 presents the topics covered by this annex by briefly indicating the
extent and type of evidence that is available. The numbers in the list above
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are used in the table to code the sources of information. Where information
is available, it is presented and examined under the main category headings.
In general, there is insufficient information, or too much overlap, to address
each of the subheadings in the text.
Table 2: Sociological and criminological evidence for ketamine
Topics Recorded evidence (see text for details)
Social consequences for the user Social consequences stem firstly from its
anaesthetic properties and from possible
loss of physical control if too high a dose
is taken and secondly from reported
psychological effects of regular, or
heavy, use which include dependency
and paranoia (4, 5, 7, 8, 9, 10)
Primary relations and/or family problems In addition to the loss of physical control,
it may cause tension due to the introspec-
tive quality of its effects, other psycholo-
gical symptoms and compulsive use by a
small minority (5, 8, 9)
Education and employment problems No evidence, but legal sanctions in
Greece, France, Ireland and Luxembourg
may result in users being dismissed from
work or education (8, 9)
Marginalisation No evidence, but related to legal
controls and sanctions, particularly 
in Greece, France, Ireland and
Luxembourg; however, this may vary
depending on the sanctions applied 
(1, 4, 5, 8, 9)
Consequences for the social behaviour Main consequences for social behaviour
of the user stem directly from ketamine effects and 
a tendency towards compulsive use by
some users (5, 7, 8, 9, 10)
Drug-related disorderly conduct No formal evidence beyond loss of
physical control related to its anaesthetic
properties (10)
Drug-related acquisitive crime No evidence of crime to finance keta-
mine use, but there is one report of
diversion from medical and veterinary
profession in France; market sales have
increased in France and the UK and
doubled in Belgium since 1995 (1, 3)
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Topics Recorded evidence (see text for details)
Drug-related violence No evidence
Drug-related traffic offences High potential for road traffic accidents
(6, 7, 8, 9)
Other social consequences
Presence or absence of major The chosen route of administration for a 
value conflicts small minority is by injection, which
raises a value conflict in a drug-using
culture which is strongly against
injecting (5, 8)
Implications for social institutions In view of potential anaesthetic and
(school, labour, recreational, etc.) numbing effects, psychological distur-
and community services bances and compulsive use, there are
implications for drug services, research
institutes, hospital emergency departments
and the press (4, 5, 6, 8, 9, 10)
Wholesale production and distribution Wholesale production, diversion distrib-
ution and/or transiting of ketamine has
been identified in four Member States
Violence in connection with wholesale Lack of sufficient data
production and distribution
Money laundering Lack of sufficient data
Involvement of organised crime In Belgium, Ireland, the Netherlands and
the UK, there appears to be involvement
of organised crime in the production
and/or trafficking of ketamine, in addition
to production and/or trafficking by these
criminal groups of amphetamine and
amphetamine-type stimulants (2)
The retail market Ketamine has marketing authorisation in
most Member States, except Greece; it is
generally indicated for special anaesthetic
and pain treatment (3)
Non-commercial ‘private’ consumption A private consumption market appears to
market among users exist for people seeking self-exploration
and a ‘near-death’ experience, but there
is no evidence about sources of supply
(5, 8, 9, 10) 
79
Topics Recorded evidence (see text for details)
Semi-public subculture consumption In dance settings, ketamine often 
market (discos, etc.) appears in the form of well-made tablets
which are visually similar to MDMA and
are usually mixed with a stimulant rang-
ing from caffeine to amphetamine; it is
also found as liquid, powder and capsules;
it is usually snorted intranasally but may
be swallowed, ‘chased’ or taken rectally
(1, 6, 8, 9, 10)
Existence and characteristics Ketamine has been used as a cutting 
of street markets agent for drugs such as cocaine, amphet-
amine and heroin and may be taken by
problem opiate users (6)
Violence, public order and nuisance No evidence
implications
Entrepreneurial criminal suppliers In Belgium, Ireland, the Netherlands and
the UK, there appears to be involvement
of organised crime in the production
and/or trafficking of ketamine (2) 
Social factors that increase the A range of factors, such as the existence
probability of harm of a large market of long-term ecstasy
users seeking new drug experiences, a
rather intellectual trend-setting image
and low price, all increase the probability
of use; other factors, such as its anaes-
thetic effects, marked discomfort with
intranasal use, the short action, acute
psychological reactions when taken
without knowledge about dose or
effects, psychological dependence and
negative effects on social relationships,
all mitigate against widespread diffusion
(5, 8, 9, 10)
Social consequences for the user
Social consequences stem firstly from poly-recreational drug users taking
ketamine in the same way and in the same quantities as they take stimulant
drugs. Some of the commonly described effects of ketamine range from (at
low doses) mild inebriation, dreamy thinking, stumbling, slurred speech and
numbness to (at higher levels) extreme difficulty moving, nausea, complete
dissociation, near-death experiences, compelling visions, blackouts, etc.
These effects depend on the dose, route of administration and the setting.
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The anaesthetic effects of ketamine reduce users’ ability to deal with social
situations and render them more liable to physical accidents. Cases of severe
cuts, burns and bruising (particularly to the user’s feet from dancing without
shoes) going unnoticed are not uncommon. The psychological effects of
ketamine use may include acute distress if taken without knowledge of its
effects and, in the context of regular or heavy use, dependence, paranoia
and egocentricity have been recorded (Kent, 1996). A general overview of
the effects is illustrated in the music press by a quotation from a celebrity
who admitted to using ketamine frequently for a couple of years:
‘Get the quantity right and it’s incredible. Get it wrong and you feel
like you’re dying.’ (Muzik magazine)
Under current laws in the European Union, the social consequences of
taking ketamine or supplying friends is significantly greater in countries such
as Greece, Ireland, Luxembourg and Norway, which have placed, or are
planning to place, ketamine under special drug controls (EMEA, 2000).
Primary relations and/or family problems
Reports of compulsive patterns of ketamine use and paranoia and egocen-
tricity linked to ketamine use reveal its potential to damage relationships.
Compulsive use of ketamine at least once a day is not uncommon. A paper
written by a regular user of ketamine in 1996 which addresses the social
consequences of ketamine use stated that:
‘Ketamine has a very cold, unemotional vibe to it [...] People have
taken ketamine chronically for a long time without suffering any sub-
stantial physical side-effects (effects on relationships, however, can be
quite substantial).’ (Kent, 1996)
In addition, novice users can encounter problems through lack of knowl-
edge. The intense dissociative effects of ketamine may be particularly prob-
lematic if it has been taken by mistake because of its similar appearance to
another drug. For example, a drug worker in the Netherlands reported two
cases of people who thought they were buying cocaine and found the unex-
pected effects of ketamine particularly distressing.
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Marginalisation
Marginalisation is more likely to be a consequence of lifestyle in general
than of ketamine use in particular. For example, ketamine may be used within
the new-age traveller community or among problem drug users or other
already marginalised groups.
A small proportion of ketamine users inject the drug intramuscularly or intra-
venously. These are usually self-exploratory ketamine users who seek to
experience a fully emergent/dissociative effect or those who have developed
tolerance and have become psychologically dependent. Injecting ketamine,
in a drug culture which is predominately anti-injecting, can lead to margin-
alisation within that culture. An illustration of marginalisation from within a
culture was given by an outreach worker in London who reported that a
woman who was found injecting ketamine in the ladies lavatories of a club
was beaten up. It was not clear who the perpetrators of the violence were,
but the reason was clearly the injecting rather than the use of ketamine itself.
There are indications that the sub-populations who inject ketamine generally
do so very discreetly and often belong to trend-setting, elite professional
groups who are least likely to suffer marginalisation (Dillon et al., 2000).
With regard to marginalisation as a result of legal sanctions, in most Member
States the social consequences of using ketamine are considerably less than
those resulting from use of other more tightly controlled drugs. In general,
the prescribed medicines laws that relate to ketamine mean that sanctions
usually apply to unauthorised suppliers rather than users.
Consequences for the social behaviour of the user
The main consequences for social behaviour stem directly from the physical
and psychological effects of ketamine and the tendency towards compulsive
use by some users. The sudden anaesthetic effects of ketamine create high
risk for accidents and make driving following consumption particularly 
dangerous. This is illustrated in the August 2000 issue of an English-language
lifestyle magazine that reported on ‘out-of-control’ recreational drug use. A
22-year-old recruitment consultant who was interviewed said:
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‘I’ve had three-day sessions (with ketamine) [...] I’ve sat on the floor
in the middle of a club not knowing who I am.’ (The Face, August
2000)
There is no evidence that acquisitive crime is committed in order to finance
ketamine use. However, theft from medical and veterinary premises has
been recorded in France. There have been a number of anecdotal reports of
diversion from legitimate sources and this is supported by reports of a sub-
stantial increase in market sales in Belgium, France and the United Kingdom
over the past few years. In Belgium, market sales have doubled since 1995
(EMEA, 2000).
A value conflict is located in the fact that the chosen route of administration
for a small minority of ketamine users is by injection, which is anathema in
the context of a recreational drug-using culture that is strongly against injecting.
This mostly applies to those users who have a psychological dependence on
ketamine or who are seeking self-exploration or a near-death experience,
where the preferred route of administration is by injection (Kent, 1996).
There are implications for a number of social institutions in relation to the
importance of doses, the anaesthetic and numbing effects of ketamine and
the potential for psychological disturbance or dependence. Responses by
some institutions are already evident in a number of Member States.
Information for drug services and outreach workers
Drug workers are key agents in prevention, harm reduction and providing
reliable information for users (Dalgarno and Shewan, 1996). In addition to
general information about contraindications and combinations, nausea and
dissociative effects, appropriate information about ketamine can vary from
one target group to another (Jansen, 2000a). For ketamine users in the dance
club scene, practical advice is now being provided by outreach workers in
dance club settings about the importance of titrating doses and about the
body-numbing effects of ketamine and consequent risk of cigarette burns
and bruised or cut feet. An outreach worker in France noted that there has
been a considerable decrease in the numbers of users falling asleep now
compared to a year ago, which she attributed to an increase in harm reduc-
tion advice about suitable recreational doses. In order to prevent ketamine
being mistaken for a stimulant drug, an outreach worker in the United
Kingdom reported that one dealer added pink food colouring to the
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ketamine to ensure that his customers knew that this signified that it was ‘his’
ketamine. The fact that ketamine does not react with commonly used field-
test kits (e.g. Marquis reagent), even though other drugs present may produce
a positive reaction, has also been made known to drug outreach workers.
For those seeking profound dissociative effects, warnings are given about
dependence, psychological distress and safe injecting.
Hospital emergency staff
Pharmacotoxicological information for staff about treatment for illicit users
of ketamine may ensure more efficient and effective treatment responses.
Research institutes
Social research on illicit use of ketamine is being initiated in some countries
and questions about ketamine have been added to European surveys targeted
at clubbers and to at least one large school survey and two magazine surveys
in the United Kingdom.
Press and mainstream media
With media coverage of all drugs, there is a danger of inadvertently promot-
ing their use by giving them publicity or of increasing harm by promoting
inaccurate information or encouraging stereotypes. It is well established
among a small number of specialist media outlets in some countries that
media can play an important role in providing evidence-based information
with emphasis on harm reduction to users and potential users. Interest
among editors of mainstream media papers appears to be growing.
Wholesale production and distribution (8)
Violence in connection with wholesale production and distribution
Member States did not provide data on violence in connection with the pro-
duction, trafficking and distribution of ketamine.
(8) Europol’s contribution to the risk assessment of ketamine.
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Money laundering
No reliable data are available on the volume of money laundering in relation
to the production, trafficking and distribution of ketamine.
Involvement of organised crime
Contributions of Member States’ law enforcement agencies
Denmark, Greece, Spain, Italy, Luxembourg, Austria and Portugal have
reported that, until now, there have been no seizures of ketamine, nor is
there any information on production, trafficking and distribution of ketamine
or on the role of organised crime in these activities.
In Belgium, 89 kg of pure ketamine powder were seized in September 1999
and, in January 2000, a seizure of 3 kg took place. There have also been a
few seizures of ketamine in tablet form, mixed with MDMA or amphetamine.
In Finland, there were 14 seizures of ketamine in 1998, totalling 614 tablets.
In 1999, 5 seizures occurred, totalling 49 tablets bearing the ‘propeller’ logo.
In France, two seizures of tablets with ecstasy-type logos containing keta-
mine and amphetamines were reported in 1998 and 1999. In September
1999, 36 bottles of ketamine were reported stolen from a veterinary clinic in
Valence.
In Germany, six people were arrested in May 1999 in relation to the seizure
of an illicit synthetic drug laboratory. A large amount of laboratory equipment
was seized, as were chemicals and end products. These included 182 g 
of ketamine hydrochloride in tablet form (700 blue tablets) and 0.9 g of
ketamine powder. Another 2 000 yellow tablets were seized containing
methamphetamine hydrochloride and ketamine hydrochloride.
In Ireland, from 1 January 1998 to 15 October 1999, there have been 43 in-
cidents of ketamine seizures. There were 40 cases in which ketamine and
ephedrine were present in tablet form (totalling 4 500 tablets); one case of
27 000 tablets with ketamine only or ketamine with caffeine; one case of 
26 tablets which contained only ketamine and one case of 0.23 g of keta-
mine powder. From 1 January to 1 June 2000, 24 individual tablet seizures
and 4 powder seizures involving ketamine occurred. Although the seizures
in Ireland could emanate from the Netherlands, it seems more likely that the
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seized drugs originated from transit transport, since no illegal laboratories
have been discovered in the Netherlands. Organised crime groups or Irish
nationals are responsible for the importation and distribution of ketamine.
There are no indications that Ireland is a transit or export point.
In the Netherlands, a single seizure of 4 barrels, containing 70 kg of ketamine,
occurred in 1999. In Sweden, there have been occasional small seizures of
ketamine.
In the United Kingdom, seizures climbed rapidly in the early 1990s. In 1995,
almost 100 000 tablets containing ketamine and ephedrine were seized.
These carried a logo commonly found on ecstasy tablets. Ketamine seizures
peaked in 1997 and over the past two years have stabilised at around 200 per
year. There have been few significant customs seizures, suggesting that most,
if not all, ketamine tablets consumed in the United Kingdom are produced
there. It is believed that ketamine raw material is imported in bulk from
legitimate suppliers in Europe and distributed through illicit drug distribution
networks.
Conclusions
The following conclusions can be made about the production and distribution
of ketamine:
 Large-scale production, trafficking and distribution of ketamine are
unknown to the law enforcement authorities of 10 Member States. Four
Member States — Belgium, Ireland, the Netherlands and the United
Kingdom — have seized considerable amounts of ketamine. However,
seizures of ketamine in the European Union are small when compared to
seizures of ‘regular’ types of synthetic drugs such as amphetamine, MDMA
and MDA.
 Two Member States, Germany and the United Kingdom, have reported illicit
production of ketamine. Production in Germany seems to be incidental.
As the ketamine seized in Ireland was imported from the Netherlands, this
would suggest that ketamine could have been produced in the latter country.
 Two Member States, Ireland and the United Kingdom, have reported on
the role of organised crime in the production, trafficking and/or distribution
of ketamine. The seizures of considerable amounts in Belgium and the
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Netherlands suggest the involvement of organised crime in the production
and/or trafficking of ketamine. With respect to the Netherlands, this is sup-
ported by information from Ireland, according to which Irish criminal
groups import ketamine almost exclusively from the Netherlands.
The retail market
The retail market appears to consist of licit ketamine diverted from legitimate
medical and veterinary establishments and illicit ketamine in various forms
prepared specifically for the recreational drug market.
Ketamine has marketing authority in most countries, except Greece, where
the marketing authorisation was recalled in 1998 (9). It is indicated for special
situations in anaesthesia and for pain treatment. According to the European
Agency for the Evaluation of Medicinal Products, its use appears to be gen-
erally decreasing, with the exception of Belgium, where its use doubled
between 1990 an 1999. The United Kingdom and France also show an
increase in market sales between 1997 and 1999 (EMEA, 2000). In Germany,
the use of ketamine remained at a consistently moderate level. Ketamine
from the pharmaceutical industry usually comes in vial/ampoules in liquid
form for intramuscular or intravenous injection and small quantities can be
obtained by mail order from chemical catalogues and the Internet at around
EUR 64 for 5 g.
Forensic science services report that illicit ketamine often appears in the
form of well-made tablets which are visually similar to MDMA and other
tablets sold as ecstasy. Typical impressions on these tablets are the same as
those found on ecstasy tablets, such as a bird, clover/club, heart,
‘Mitsubishi’, etc. These tablets have been widely distributed, usually mixed
with a stimulant such as ephedrine and/or caffeine. Ketamine is also found
on the ‘illicit recreational’ drug market as liquid, powder and capsules, in
which case it is snorted, swallowed or occasionally ‘chased’. Some synonyms
for ketamine are ‘K’, ‘ket’ and ‘special K’, although, as with logos, these may
(9) Classification for the supply of medicinal products for human use is regulated by Directive 92/26/EEC
of 31 March 1992. Article 12 of Directive 75/319/EEC of 20 May 1975 regulates, through the
Committee for Proprietary Medicinal Products (CPMP), the suspensions, withdrawal or variations
to the terms of the marketing authorisation, in particular to take account of the information collected
in accordance with pharmacovigilance.
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change over time. In one recreational market for homosexual men in the
United Kingdom, ketamine was coloured pink and sold in plastic wraps
sealed with a pink fairy, to distinguish the product from others. This sold for
approximately EUR 80.
Ketamine has also been used as a cutting agent for drugs such as cocaine,
amphetamine and heroin. It can be bought over the counter in some Asian
countries and one outreach worker in the United Kingdom reported that
financially solvent users travel to countries such as Goa to purchase supplies,
mainly for personal use and for their friends.
Easy availability of ketamine at relatively low prices renders it unlikely that
illicit tablet manufacturers would contemplate the synthesis of ketamine,
which is probably too difficult for most clandestine chemists. This is likely to
limit the potential for a lucrative market.
Social factors that increase the probability of harm
The existence of a large market of long-term ecstasy users who are seeking
new drug experiences and the upmarket, trend-setting image associated with
ketamine increase the probability of its use. These factors, together with a
lack of information about doses and effects, increase the probability of harm.
Attitudes to drugs play an important part in the diffusion of drug trends and
there is an obvious link between an individual’s willingness to try a drug and
his/her perceptions about the health risks involved. This has been shown to
be linked to whether or not the individual has been exposed to, or has expe-
rienced, the drug in question. This complex relationship is demonstrated by
different attitudes in Europe to ketamine use and beliefs about the health
risks. For example, a survey of 346 young people attending raves in Vienna,
found that young people (who were regularly taking ecstasy and ampheta-
mine) considered that the psychological risks attached to taking ketamine
were very high. Use of ketamine among this Austrian survey population was
low. However, a different attitude was found in a survey of London clubbers
in which 40 % of respondents said they had tried ketamine and a substantial
number planned to use it again (Release, 1997).
88
Some specific ketamine facts may mitigate against widespread diffusion and
subsequent harm. The relatively low availability, short action of effects and
unpredictable doses with subsequent unwanted physical effects are all factors
that are likely to retard diffusion. Discomfort with intranasal use of ketamine
is another factor which has been reported by users to be far more marked
with ketamine than with stimulant drugs taken in this way. One regular ketamine
user reported:
‘I personally can’t handle the stinging, burning, watering eyes, and
awful metallic-anaesthetic taste in the back of my throat.’ (Kent, 1996)
The acute psychological reactions when ketamine is taken without prior
knowledge about dosage or effects, the danger of dependency and negative
effects on social relationships are also factors which may give the drug a
negative image among potential users.
It has been suggested that the growth in ketamine use may be linked to the
poor quality of ecstasy between 1997 and 1998. The factors which mitigate
against the diffusion of ketamine use highlight some important aspects in
which ketamine is different to MDMA. One further perceived difference
between ketamine and MDMA relates to the fact that ketamine cannot com-
pete with MDMA’s effect of enhancing the sound of music and its role in the
music industry. A music magazine claimed that research into ketamine
demonstrates that ketamine narrows the auditory band width, cutting out
some frequencies, which reduces the capacity of ketamine to link with
music, although ketamine may enhance very specific types of music or
sound (Muzik, 2000). MDMA’s association with a wide range of music has
been an important and widely recognised factor in its diffusion (Shapiro,
1999).
In summary, an answer to a music media question posed in the headline of
an article about ketamine — ‘Everything started with an E. Will it end with a
K?’ — is that the sociological evidence suggests that it is unlikely that keta-
mine will compete with ecstasy as a drug of widespread diffusion.
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Public health risks — epidemiological
evidence
Introduction
Non-medical use of ketamine was recognised over 20 years ago in the
United States when the Food and Drinks Administration (FDA) expressed
concerns about it in 1979. However, it did not come to public notice in
Europe until the 1990s. In 1995 and 1996, concern in the United Kingdom
about the prevalence of misuse and the health risks associated with ketamine
escalated following a seizure of almost 100 000 ketamine tablets. These
carried a logo commonly found on ecstasy tablets and some users suffering
anxiety attacks were hospitalised after taking large doses of ketamine believ-
ing it to be ecstasy.
This report summarises the relevant data required by Technical Annex D of
the guidelines for the risk assessment of new synthetic drugs. In the absence
of systematic studies of non-medical use of ketamine, the epidemiological
evidence is based on information collected from:
 the Reitox national focal points in the 15 EU Member States (1);
 Europol’s contribution to the risk assessment of ketamine (2);
 the EMEA contribution to the risk assessment of ketamine (3);
 the Qualitative European Drugs Network (QED) (4);
 the literature (5);
 key European forensic scientists (6);
 key toxicologists in the United Kingdom (7);
 telephone interviews with international experts in the field of recreational
drugs (8);
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 the Internet (English-language searches) (9); and
 youth and mass media (English-language searches) (10).
Table 3 presents the topics covered by this annex by briefly indicating the
extent and type of evidence that is available. The numbers in the list above
are used in the table to code the sources of information. Where information
is available, it is presented and examined under the main category headings.
In general, there is insufficient information, or too much overlap, to address
each of the subheadings in the text.
Table 3: Topics for public health risks: epidemiological evidence
Topics Recorded evidence (see text for details)
Availability and quality of product 
on the market
Availability at consumer level Seizures and limited targeted survey data
(extent/quantities) indicate relatively low availability and
use outside of specific settings 
(1, 2, 4, 6, 8)
Sources (at consumer level) Diversion from licit supply, illicit pro-
duction of ‘ecstasy’ type tablets and
foreign purchases, particularly from Asia
(1, 2, 6, 8, 9)
Trends in availability Appears to be decreasing in the UK and
increasing in some other Member States
(1, 2, 6)
Average dose and degree of variability Depending on the concentration, form
and method of administration, recre-
ational doses range from 30 to 300 mg
(1, 5, 6, 8, 9, 10)
Purity levels and presence of adulterants No systematic evidence
Other active ingredients Forensic laboratory analyses in the EU
have found ketamine mixed with manitol,
caffeine, ephedrine, MDMA, ampheta-
mine and methamphetamine (1, 2, 6)
Typical prices and range Ranges from EUR 15 to 80 per g (6, 8, 9)
Knowledge, perceptions and 
availability of information
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Topics Recorded evidence (see text for details)
Availability of scientific information See the review of the pharmacotoxico-
on product logical data on ketamine
Availability of information on effects Ranges from mild inebriation to visions
of product and blackouts (8, 9, 10)
Level of awareness of product amongst Relatively low awareness and experi-
drug consumers in general mentation in Europe, but one targeted
survey of clubbers in the UK found that
up to 40 % have experimented with ket-
amine (4, 8)
Level of knowledge about product, Lack of chemical information about 
effects and perceptions among doses, but anecdotal reports from France
consumers of product and the UK indicate growing awareness
among consumers about better manage-
ment of doses and negative effects 
(8, 9, 10)
General population No evidence, but appears low
Prevalence and patterns of use
Extent of use of product Targeted surveys and anecdotal reports
indicate limited prevalence outside
specific settings (8, 10)
Frequency of use No evidence, but regular/heavy users
report a tendency to psychological
dependence (5, 8, 9, 10)
Route(s) of administration Mostly intranasal, but also ‘chased’,
swallowed, administered rectally or
injected (5, 8, 9, 10)
Other drugs used in combination Frequently used with, or cut with, 
with product a range of stimulants (5, 6, 8, 10)
Geographical distribution of use In France and the UK, use is mainly in
the free-party/new-age traveller scene
and among experienced MDMA users
and drug trendsetters (8)
Trends in prevalence and patterns of use Some evidence of declining use in the
UK, whilst increasing in Belgium and
France (1, 2, 3)
Characteristics and behaviour of users
Age and gender of users Anecdotal reports of use among older,
experienced drug users (8)
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Topics Recorded evidence (see text for details)
Social groups where product Experienced MDMA users, free-party/
available/used new-age traveller scene, homosexual
populations, small groups of self-
exploratory individuals and as a sec-
ondary drug by some opiate dependents
(5, 8, 9, 10)
Risk behaviours associated with use Physical accidents and psychological
dependence or distress (7, 8, 9, 10)
Special concerns about vulnerable The most vulnerable groups are those
groups people who take ketamine under the
illusion they are taking MDMA or
another stimulant drug (2, 6, 8, 9, 10)
Trends in characteristics/behaviours Among outreach workers in party settings
of users there are some reports of marked improve-
ments in users managing their doses to
avoid blackouts and other physical risks;
concern exists regarding tolerance and
psychological dependence (8, 9, 10)
Indicators of health consequences
Hospital emergencies 17 intoxications are confined to one
French report; there are some references
to harm in EMEA pharmacovigilance
reports (1, 3, 5)
Deaths (direct and indirect) One death associated with ketamine in
France and two deaths in Ireland in 1996
in which ketamine was found (1, 5)
Traffic accidents No evidence
Requests for treatment/counselling No evidence, but anecdotal reports from
drug outreach workers of users needing
support and information (8)
Other health indicators Concerns expressed by drug outreach
workers and music media journalists
about its anaesthetic effects in dance
settings (8, 9, 10)
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Following an EMCDDA request to all 15 Reitox national focal points for
information about ketamine, five responded stating that they were unable to
provide any official evidence of non-medical ketamine use in their countries
(Denmark, Italy, Luxembourg, Austria and Portugal). Austria provided some
anecdotal reports of its use.
Forensic laboratory analysis of samples of ketamine were reported by eight
countries, either by the focal points or by Europol. The number of seizures
and quantities of ketamine identified by laboratory analysis range from 89 kg
in 1999 in Belgium to occasional small seizures in France and Sweden.
Three deaths have been reported in the European Union in which ketamine
was identified by laboratory analysis: two in Ireland in 1996 and one in
France. Ketamine was not considered to be the cause of death in the Irish
cases and few details are available about the French death. Non-fatal hospital
admissions associated with ketamine are difficult to assess in the absence of
routine screening for ketamine by hospital toxicology laboratories. Medical
staff may not distinguish symptoms of ketamine overdose from other drug
overdoses or general psychiatric symptoms, which are mainly psychological
or related to loss of physical control.
The main epidemiological indicators for ketamine use are summarised in
Table 4.
Topics Recorded evidence (see text for details)
Context of use
Risk factors linked to circumstances Insufficient knowledge about doses and 
and rituals of consumption adoption of the same consumption
patterns for ketamine as those used for
other stimulant drugs increase the health
risks; tolerance and psychological
dependence resulting from regular use
may produce a tendency to gravitate to
injecting ketamine (5, 7, 8, 9, 10)
Implications for the non-using population Ketamine entering the recreational drug
market in the guise of ecstasy or other
stimulant drugs means that it may be
taken inadvertently (1, 2, 6, 8)
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Availability and quality of product on the market
Ketamine has marketing authorisation in most countries in the EU, except
Greece, where the authorisation was recalled in 1998 (10). In human medicine,
ketamine is indicated for special situations in anaesthesia and for pain treat-
ment. In Ireland, ketamine is not used in human medicine and the govern-
ment plans to add it to the list under the Misuse of Drugs Act. Elsewhere in
the EU, licit use of ketamine is generally limited and is decreasing, with the
exception of Belgium, Germany, France and the United Kingdom. In Belgium,
its use has doubled in the past 10 years, although it has been controlled by
royal decree since 1976. In many countries, ketamine is subject to restricted
prescription or is regulated as a psychotropic substance so that unauthorised
supply is illegal (EMEA, 2000).
Seizures
Seizure data suggest different levels of availability of ketamine within different
Member States, with a decrease occurring in the United Kingdom and an
increase in some other Member States (Europol, 2000). A large proportion of
ketamine seizures are in tablet form and the tablets carry the same logos as
those often found on ecstasy tablets. Synonyms such as ‘K’ and ‘special K’
are used. Forensic laboratory analysis has found ketamine, in variable doses,
mixed with manitol, caffeine, ephedrine, MDMA, amphetamine and
methamphetamine.
In Belgium, 89 kg of pure ketamine in powder form was seized in September
1999 and a further 3 kg in January 2000. Some tablets seized in Belgium also
contained MDMA or amphetamine. In Denmark, no seizures have been
reported. In Greece, three seizures have been reported, the most recent of
which was from two British men on a Greek island in June 2000. They had
in their possession 56 tablets containing ketamine and caffeine and bearing
the ‘Mitsubishi’ logo. In Ireland, most seizures of ketamine took place in 1998,
including a seizure of 27 000 tablets, some of which contained a mixture of
ketamine and caffeine. One seizure was of ketamine in powder form. Since
April 1999, only four cases have been recorded and ephedrine was present
(10) Classification for the supply of medicinal products for human use is regulated by Directive 92/26/EEC
of 31 March 1992. Article 12 of Directive 75/319/EEC of 20 May 1975 regulates, through the
Committee for Proprietary Medicinal Products (CPMP), the suspensions, withdrawal or variations
to the terms of the marketing authorisation, in particular to take account of the information collected
in accordance with pharmacovigilance.
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in all of these. It is believed that the vast majority of tablets seized in Ireland
originated in the Netherlands. In Spain, early seizures took place in 1995 in
the Balearic Islands and, in 1996, ketamine seized in Barcelona was found
to be mixed with manitol. Between 1995 and 1996, an English police team
visited the Balearic Islands to investigate the origin of ketamine tablets that
had been seized in discotheques and bars and were suspected to have been
manufactured in the United Kingdom. The seizures in Spain have been
mainly from foreign tourists and none have occurred in Madrid and other
major cities. In Sweden, there have been occasional small seizures of keta-
mine. Ketamine is an integral part of four different medicinal products and
some years ago stolen ketamine products from the legal pharmaceutical
trade appeared on the illegal market.
In the United Kingdom, seizures climbed rapidly in the early 1990s and then
levelled out. A definite decline has occurred over the past year. In the
January to March period of 1999, ketamine constituted 10 % of all illicit
drug seizures. In the same period for 2000, ketamine dropped to 1.4 % of all
illicit drug seizures. This decrease is believed to be due to a number of
police investigations, particularly in the north-west of England. There have
been few significant customs seizures, suggesting that most, if not all, of the
tablets consumed in the United Kingdom are produced there. It is believed
that ketamine raw material is imported in bulk from legitimate suppliers in
Europe. A number of ketamine tablet manufacturers in the United Kingdom
have been successfully prosecuted for conspiracy to supply, or attempt to
supply, a controlled drug. Some dealers have been prosecuted for conspiracy
to defraud contrary to common law.
Other information sources close to ketamine users in the United Kingdom
and France suggest that there may be diversion from licit medical and
veterinary suppliers and from foreign purchases, particularly from Asia.
Dose and price
Depending on the concentration, form and method of administration, recre-
ational doses range from 30 to 300 mg and timing varies in both onset and
duration. For example, an average intramuscular dose is 25–50 mg with an onset
of 1–5 minutes and a duration time of 45–90 minutes. An average oral dose is
75–300 mg with an onset of 5–20 minutes and duration of 90 minutes. The
effects of nasal doses have been described as quite different from other
administration routes at low doses. An average nasal dose is 30–75 mg with
an onset of 2–25 minutes and a duration time of only 10–30 minutes.
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Prices range from EUR 15 to EUR 80 per gram and anecdotal reports suggest
that, at such low prices, the illicit trade in ketamine is unlikely to be a lucra-
tive one. A combination of ketamine and cocaine has also been reported and
this is called ‘special CK’, with reference to Calvin Klein, the popular
American designer.
Knowledge, perceptions and availability of information
There appears to be relatively low awareness and experimentation with
ketamine in Europe compared with drugs such as cannabis, MDMA,
amphetamine and cocaine. Lack of information about the dose content of
the ketamine on the market is an important factor, according to outreach
workers. Anecdotal reports from France and the United Kingdom indicate a
growing awareness among consumers about how to manage doses to
achieve sought-after effects and avoid negative ones. At low doses, ketamine
is reported to have some stimulant effect. This could be the result of the stim-
ulant effect of active cutting agents or because ketamine is often sniffed with
amphetamine and/or cocaine or taken with other drugs in the ‘illicit recre-
ational’ drug scene. Ketamine may also be administered in a series of intra-
venous or intramuscular doses for a specific ketamine experience. Numerous
books and journal articles have been written concerning ketamine.
Information about the effects, supply and health risks is provided on Internet
web sites and newsgroups such as www.erowid.org and alt.drugs. Terms
such as ‘K hole’ are used by conscious consumers of ketamine to describe
and locate the effects of the drug.
Perceptions
Anecdotal reports suggest that ketamine has an upmarket image as an esoteric
drug for experienced recreational drug users. The major advantages of keta-
mine from the user’s perspective are: fast onset and recovery and minimal
effect on cough and gag reflexes, thus reducing the risk of choking on saliva
or vomit (Jansen, 2000). Internet newsgroups have made comparisons
between ketamine and DXM (dextromethorphan), advising that DXM has a
considerably longer half life and worse side-effects than ketamine for most
people. Forensic scientists and toxicologists, however, have drawn attention
to close similarities to phencyclidine (a Class A controlled drug in a number
of countries) and to the (non-controlled) veterinary anaesthetic tiletamine.
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Prevalence and patterns of use
The trend in non-medical use of ketamine appears to be decreasing in the
United Kingdom and increasing in France and possibly Belgium and some
other Member States. Targeted surveys of clubbers and a limited number of
school surveys are the major source of information about prevalence and
patterns of ketamine use. These have shown that a significant number of
people experiment with ketamine but that the level varies between sub-
populations and geographical areas. A London club survey in 1997 found
that up to 40 % of the 200 respondents had experimented with ketamine and
many were planning to use it that evening (Release, 1997). This survey
placed ketamine in fourth place after cannabis, amphetamine and ecstasy. A
large French survey conducted in 1997 found that 15 % of 900 respondents
in techno party settings had experimented with ketamine (Médecins du
Monde, 1999), whereas, among a matched control group of young people
who did not go to techno events, consumption of ketamine was non-existent.
Another survey targeted at a dance setting in Austria found that respondents
who were regularly taking MDMA and amphetamine considered that the
psychological risks attached to taking ketamine were very high.
Recently a large (over 1 500 respondents) school survey conducted in the
north-east of England found that 1 % of 13/14-year-old children and 2 % of
15/16-year-olds had tried ketamine compared with 2 and 5 %, respectively,
who had tried cocaine (Centre for Social Marketing, 2000). In Greece, dur-
ing 1999, treatment services and telephone helplines reported some
ketamine use in the same recreational scenes as ecstasy and cocaine.
Ketamine in its pharmacological presentation is usually sniffed as a powder
or injected, but there have been reports of it being swallowed, inhaled by
‘chasing’ and inserted rectally. There are no reports of demand for treatment
of ketamine-related problems from drug treatment services in Member
States, but there appears to be a consensus among drug outreach workers,
and users themselves, that regular ketamine use may lead to psychological
dependence.
Characteristics and behaviour of users
Targeted surveys and anecdotal reports indicate that prevalence may be
higher in older, experienced MDMA users, particularly in the free-party/new-
age traveller scene, among homosexual populations and among small
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groups of self-exploratory individuals. A study of 100 ketamine users con-
ducted by the Australian National Drug and Alcohol Research Centre reported
that there appeared to be four primary user groups (Dillon et al., 2000):
injecting heroin users, members of the gay scene, regular drug users in the
dance scene, and ‘self-exploratory’ users who like to take the drug in isolation
and ‘astro travel’. Among ‘closed’ groups in Europe, initiation into ketamine
use is often ritualised. On such occasions, ketamine is given gratis.
It has been suggested by a number of different sources that the physical
clumsiness, falling asleep and blackouts that are commonly reported by keta-
mine users are not tolerated in high-street and music-club settings. One out-
reach worker in the United Kingdom free-party scene observed that:
‘... it’s more popular at free parties because you can lie/fall down
wherever you like and not get grief for spilling your drink all over
someone’s Pradas.’ (Telephone interview)
Among outreach workers in party settings in both London and Paris there are
reports of marked improvements among ketamine users in their ability to
manage their doses in order to avoid blackouts and other physical risks
(Dalgarno and Shewan, 1996). There are also reports of people with chronic
opiate problems using ketamine for its anaesthetic and analgesic effects.
The most vulnerable group of users are those who take ketamine under the
illusion that they are taking MDMA or some other stimulant drug. The volume
of seizures of ketamine in tablet form with ecstasy-type logos reflects the
scope for this scenario and the need for better information about drug con-
tents and harm reduction. Compared with the effect of stimulants, the rapid
physical incapacity rendered by ketamine consumption has serious implica-
tions for driving.
Indicators of health consequences
In the European Union, there have been three deaths reported to the 
EMCDDA in which ketamine was found by laboratory analysis. Two of these
occurred in 1996 in Ireland. In one, there was a history of ecstasy use and
ketamine and opiates were found. In the other case, ketamine, ephedrine
and pseudoephedrine were found. In neither of the Irish cases was ketamine
considered to be the main cause of death. One death of a 19-year-old male
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has been reported in France in which ketamine, LSD and ecstasy were impli-
cated. Further details regarding this case were not available at the time of
writing (Arditti, 2000).
There has been a notable lack of reporting about hospital emergencies asso-
ciated with ketamine. A recent report prepared in France presents some data
on 17 cases of intoxication associated with ketamine. The report describes
conditions such as difficulties in walking, agitation, fever and psychological
disturbances (Arditti, 2000).
Health concerns have been expressed by drug outreach workers and music
media journalists about the anaesthetic effects of ketamine in dance settings
and sudden, unexpected, effects. Lack of information about doses and the
adoption of the same consumption patterns for ketamine as for other stimu-
lant drugs increase the potential for undesirable effects. In clubs, security
staff are sometimes quick to remove a person who has fallen asleep and
leave them in the street. According to outreach workers, risks such as these
could be overcome with adequate information and appropriate warnings. 
A further health risk concerns the risk of tolerance and psychological depen-
dence resulting from regular use (Jansen, 2000a). Where there is depen-
dence, there may be a tendency to gravitate towards injecting ketamine.
Context of use
An important factor with regard to context of use is the lack of reliable
dosage information accompanying sales of ketamine at street level. In the
absence of advice or previous experience, first-time users of ketamine tend
to follow similar consumption patterns as for other drugs. Such uninformed
use of ketamine increases the risk of both physical and psychological
problems. Outreach workers report that ritualised care is often given to first-
time users by others to avoid such risks. Individuals who take ketamine mis-
takenly for MDMA or another stimulant may have no prior knowledge or
ameliorative support.
Short-duration effects are not generally viewed as value for money by recre-
ational drug users. However, in the context of ketamine’s less sought-after 
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anaesthetic effects, the short duration may be viewed as an advantage. One
music magazine refers to this particular ‘advantage’ of ketamine: 
‘The great thing is it wears off pretty quick. If you see a girl you like,
you can give it a rest for half and hour and chat her up without making
an idiot of yourself.’ (Muzik)
Implications for the non-using population
The main implication for the non-ketamine-using population appears to be
the phenomenon of ketamine entering the recreational drug market in the
guise of ecstasy or other stimulant drugs. This means that someone expect-
ing to take MDMA, cocaine or amphetamine may find themselves inadver-
tently taking ketamine, without warning, knowledge or support.
Table 4: Summary of key data on ketamine
Date Place Comment
Illicit use 1970s United States Indications of illicit use
first identified 1990 United Kingdom First indications of illicit use
1995 Spain — Balearic 
Islands
Legal controls 1976 Belgium Control by decree
1987 Greece Control under law, List A
1996 United Kingdom Control under Medicines Act; 
ACMD recommend monitoring 
but not control
1997 Aug. France Derivatives (excluding injectables)
controlled under Narcotic Act 
entered into force
1999 Aug. United States Classified as controlled 
Schedule 3 substance
2000 Ireland Plans to control under the 
Misuse of Drugs Act
Luxembourg Special legal status with narcotic
drug-type restrictions
Large seizures 1995 United Kingdom Almost 100 000 tablets in one
seizure
1998 Ireland 27 000 tablets in one seizure
1999 Netherlands 4 barrels containing 70 kg
1999 Sep. Belgium 89 kg pure ketamine powder
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Date Place Comment
Small seizures/ 1995–99 Spain — Balearic 6 seizures of 409 tablets and 
market studies Islands and series of small seizures
Barcelona
1998–99 Ireland 42 seizures of 4 500 tablets
2000 24 individual tablet seizures 
Jan.–June and 4 powder seizures involving
ketamine
1998–99 Finland 19 seizures totalling 660 tablets
with ecstasy logo
1998–99 United Kingdom Seizures stabilised at approx. 
200 a year and recently 
decreased from ketamine 
accounting for 10 % of all illicit 
seizures to 1.4 %
1999–2000 Greece 3 seizures, 2 in powder and 
1 in tablet form
1998–99 France — d’Aquitaine, 2 seizures of tablets with 
Rhone-Alpes ecstasy-type logo
1999 Sep. France — Valence 36 bottles of ketamine reported 
stolen from a veterinary clinic
2000 Jan. Belgium 3 kg of powder seized
Laboratory/ During United Kingdom A number of ketamine tablet 
other supply 1990s manufacturers prosecuted
investigations 1999 May Germany Equipment and 700 blue tablets
and 2 000 yellow tablets and
0.9 g powder
Deaths 1996 Ireland Two deaths, but ketamine was 
associated not recorded as the main cause
with ketamine ? France — Paris 19-year-old male — LSD and
ecstasy
Non-fatal 1991–2000 France — six 17 recorded intoxications
intoxication different cities
Source notes — It is notable that there is an absence of recorded deaths — in
which ketamine was recorded as the main cause — and intoxications, particularly
in relation to seizures. Also there are few data on seizures, because in most EU
Member States ketamine it is not usually controlled by drug laws. 
Pattern and effects — There is a large body of literature on both positive and
negative effects. It appears to have relatively high status among experienced
MDMA users. It is sold in the ecstasy market and is often in tablet form physically
indistinguishable from ecstasy. It is also found in powder and liquid form imported
from abroad or diverted from medical or veterinary sources. In ‘closed’ settings, it
is used for psychic exploration.
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Health risks — The main acute risks are accidents as a result of lack of knowledge
about dose and fast-acting anaesthetic effects and risk of triggering psychiatric
symptoms. Tolerance resulting in psychological dependence is highlighted as a
risk for a limited number of individuals.
Mode and scope — Reports suggest that ketamine is not widely used and,
although it may be sold as ‘ecstasy’ or another stimulant drug, it is different in a
number of important ways. For a number of reasons related to factors associated
with drug diffusion, it is unlikely to gain the widespread popularity of MDMA. 
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